



US011207527B2

(12) **United States Patent**
An et al.

(10) **Patent No.:** **US 11,207,527 B2**
(45) **Date of Patent:** **Dec. 28, 2021**

(54) **METHOD AND SYSTEM FOR DETERMINING AN ATRIAL CONTRACTION TIMING FIDUCIAL IN A LEADLESS CARDIAC PACEMAKER SYSTEM**

(58) **Field of Classification Search**
CPC .. A61N 1/3684; A61N 1/3627; A61N 1/3756; A61N 1/36585; A61N 1/3682;
(Continued)

(71) Applicant: **CARDIAC PACEMAKERS, INC.**, St. Paul, MN (US)

(56) **References Cited**

(72) Inventors: **Qi An**, Blaine, MN (US); **Yinghong Yu**, Shoreview, MN (US); **Pramodsingh Hirasingsh Thakur**, Woodbury, MN (US); **Krzysztof Z. Siejko**, Maple Grove, MN (US)

U.S. PATENT DOCUMENTS

3,486,506 A 12/1969 Auphan
3,659,615 A 5/1972 Enger
(Continued)

(73) Assignee: **CARDIAC PACEMAKERS, INC.**, St. Paul, MN (US)

FOREIGN PATENT DOCUMENTS

AU 2008279789 B2 10/2011
AU 2008329620 B2 5/2014
(Continued)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 757 days.

OTHER PUBLICATIONS

(21) Appl. No.: **15/642,121**

US 8,116,861 B2, 02/2012, Root et al. (withdrawn)
(Continued)

(22) Filed: **Jul. 5, 2017**

(65) **Prior Publication Data**
US 2018/0008829 A1 Jan. 11, 2018

Primary Examiner — Deborah L Malamud
(74) *Attorney, Agent, or Firm* — Seager, Tufte & Wickhem LLP.

Related U.S. Application Data

(60) Provisional application No. 62/359,055, filed on Jul. 6, 2016.


(57) **ABSTRACT**

(51) **Int. Cl.**
A61N 1/365 (2006.01)
A61N 1/372 (2006.01)
(Continued)

Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system is disclosed. An electrical cardiac signal associated with an atrial contraction of the patient's heart and a mechanical response to the atrial contraction of a patient's heart are used to determine an atrial contraction timing fiducial. A ventricle pacing pulse may then be generated an A-V delay after the atrial contraction timing fiducial.

(52) **U.S. Cl.**
CPC *A61N 1/36585* (2013.01); *A61N 1/36535* (2013.01); *A61N 1/36542* (2013.01);
(Continued)

10 Claims, 13 Drawing Sheets



(51)	Int. Cl.		5,058,581 A	10/1991	Silvian
	<i>A61N 1/39</i>	(2006.01)	5,078,134 A	1/1992	Heilman et al.
	<i>A61N 1/375</i>	(2006.01)	5,109,845 A	5/1992	Yuuchi et al.
(52)	U.S. Cl.		5,113,859 A	5/1992	Funke
	CPC	<i>A61N 1/36578</i> (2013.01); <i>A61N 1/3756</i>	5,113,869 A	5/1992	Nappholz et al.
		(2013.01); <i>A61N 1/37205</i> (2013.01); <i>A61N</i>	5,117,824 A	6/1992	Keimel et al.
		<i>1/37288</i> (2013.01); <i>A61N 1/37512</i> (2017.08);	5,127,401 A	7/1992	Grevious et al.
		<i>A61N 1/3925</i> (2013.01); <i>A61N 1/3962</i>	5,133,353 A	7/1992	Hauser
		(2013.01); <i>A61N 1/39622</i> (2017.08)	5,144,950 A	9/1992	Stoop et al.
(58)	Field of Classification Search		5,170,784 A	12/1992	Ramon et al.
	CPC	<i>A61N 1/36578</i> ; <i>A61N 1/37205</i> ; <i>A61N</i>	5,179,945 A	1/1993	Van Hofwegen et al.
		<i>1/362</i> ; <i>A61N 1/365</i> ; <i>A61N 1/3702</i> ; <i>A61N</i>	5,179,947 A	1/1993	Meyerson et al.
		<i>1/36</i> ; <i>A61N 1/08</i> ; <i>A61N 1/36139</i> ; <i>A61N</i>	5,193,539 A	3/1993	Schulman et al.
		<i>1/36842</i> ; <i>A61N 1/37</i> ; <i>A61N 1/3714</i> ;	5,193,540 A	3/1993	Schulman et al.
		<i>A61N 1/0504</i> ; <i>A61B 5/0452</i> ; <i>A61B</i>	5,241,961 A	9/1993	Henry
		<i>5/04012</i> ; <i>A61B 5/0402</i> ; <i>A61B 5/042</i> ;	5,243,977 A	9/1993	Trabuocco et al.
		<i>A61B 5/6869</i> ; <i>A61B 5/4836</i> ; <i>A61B 5/04</i> ;	5,259,387 A	11/1993	DePinto
		<i>A61B 5/7282</i> ; <i>A61B 5/02</i> ; <i>A61B 5/024</i> ;	5,269,326 A	12/1993	Verrier
		<i>A61B 2560/0462</i> ; <i>A61B 2562/0209</i> ;	5,284,136 A	2/1994	Hauck et al.
		<i>A61B 5/0006</i> ; <i>A61B 5/0245</i>	5,300,107 A	4/1994	Stokes et al.
		See application file for complete search history.	5,301,677 A	4/1994	Hsung
(56)	References Cited		5,305,760 A	4/1994	McKown et al.
	U.S. PATENT DOCUMENTS		5,312,439 A	5/1994	Loeb
			5,313,953 A	5/1994	Yomtov et al.
			5,314,459 A	5/1994	Swanson et al.
			5,318,597 A	6/1994	Hauck et al.
			5,324,316 A	6/1994	Schulman et al.
			5,331,966 A	7/1994	Bennett et al.
			5,334,222 A	8/1994	Salo et al.
			5,342,408 A	8/1994	deCoriolis et al.
			5,370,667 A	12/1994	Alt
			5,372,606 A	12/1994	Lang et al.
			5,376,106 A	12/1994	Stahmann et al.
			5,383,915 A	1/1995	Adams
			5,388,578 A	2/1995	Yomtov et al.
			5,404,877 A	4/1995	Nolan et al.
			5,405,367 A	4/1995	Schulman et al.
			5,411,031 A	5/1995	Yomtov
			5,411,525 A	5/1995	Swanson et al.
			5,411,535 A	5/1995	Fujii et al.
			5,438,990 A	8/1995	Wahlstrand et al.
			5,441,527 A	8/1995	Erickson et al.
			5,456,691 A	10/1995	Snell
			5,458,622 A	10/1995	Alt
			5,466,246 A	11/1995	Silvian
			5,468,254 A	11/1995	Hahn et al.
			5,472,453 A	12/1995	Alt
			5,496,361 A	3/1996	Moberg et al.
			5,522,866 A	6/1996	Fernald
			5,529,578 A	6/1996	Struble
			5,540,727 A	7/1996	Tockman et al.
			5,545,186 A	8/1996	Olson et al.
			5,545,202 A	8/1996	Dahl et al.
			5,549,650 A	8/1996	Bornzin et al.
			5,571,146 A	11/1996	Jones et al.
			5,591,214 A	1/1997	Lu
			5,620,466 A	4/1997	Haefner et al.
			5,634,938 A	6/1997	Swanson et al.
			5,649,968 A	7/1997	Alt et al.
			5,662,688 A	9/1997	Haefner et al.
			5,674,259 A	10/1997	Gray
			5,683,426 A	11/1997	Greenhut et al.
			5,683,432 A	11/1997	Goedeke et al.
			5,697,958 A	12/1997	Paul et al.
			5,706,823 A	1/1998	Wodlinger
			5,709,215 A	1/1998	Perttu et al.
			5,720,770 A	2/1998	Nappholz et al.
			5,722,998 A	3/1998	Prutchi et al.
			5,728,154 A	3/1998	Crossett et al.
			5,741,314 A	4/1998	Daly et al.
			5,741,315 A	4/1998	Lee et al.
			5,752,976 A	5/1998	Duffin et al.
			5,752,977 A	5/1998	Grevious et al.
			5,755,736 A	5/1998	Gillberg et al.
			5,759,199 A	6/1998	Snell et al.
			5,774,501 A	6/1998	Halpern et al.
			5,792,195 A	8/1998	Carlson et al.
			5,792,202 A	8/1998	Rueter
			5,792,203 A	8/1998	Schroepfel

(56)

References Cited

U.S. PATENT DOCUMENTS

5,792,205	A	8/1998	Alt et al.	6,292,698	B1	9/2001	Duffin et al.
5,792,208	A	8/1998	Gray	6,295,473	B1	9/2001	Rosar
5,814,089	A	9/1998	Stokes et al.	6,297,943	B1	10/2001	Carson
5,827,216	A	10/1998	Igo et al.	6,298,271	B1	10/2001	Weijand
5,836,985	A	11/1998	Rostami et al.	6,307,751	B1	10/2001	Bodony et al.
5,836,987	A	11/1998	Baumann et al.	6,312,378	B1	11/2001	Bardy
5,842,977	A	12/1998	Lesho et al.	6,315,721	B2	11/2001	Schulman et al.
5,843,132	A	12/1998	Ilvento	6,336,903	B1	1/2002	Bardy
5,855,593	A	1/1999	Olson et al.	6,345,202	B2	2/2002	Richmond et al.
5,873,894	A	2/1999	Vandegriff et al.	6,348,070	B1	2/2002	Teissl et al.
5,891,175	A	4/1999	Walmsley et al.	6,351,667	B1	2/2002	Godie
5,891,184	A	4/1999	Lee et al.	6,351,669	B1	2/2002	Hartley et al.
5,895,414	A	4/1999	Sanchez-Zambrano	6,353,759	B1	3/2002	Hartley et al.
5,897,586	A	4/1999	Molina	6,358,203	B2	3/2002	Bardy
5,899,876	A	5/1999	Flower	6,361,780	B1	3/2002	Ley et al.
5,899,928	A	5/1999	Sholder et al.	6,366,811	B1	4/2002	Carlson
5,919,214	A	7/1999	Ciciarelli et al.	6,368,284	B1	4/2002	Bardy
5,935,078	A	8/1999	Feierbach	6,371,922	B1	4/2002	Baumann et al.
5,941,906	A	8/1999	Barreras, Sr. et al.	6,398,728	B1	6/2002	Bardy
5,944,744	A	8/1999	Paul et al.	6,400,982	B2	6/2002	Sweeney et al.
5,954,757	A	9/1999	Gray	6,400,990	B1	6/2002	Silvian
5,970,986	A	10/1999	Bolz et al.	6,408,208	B1	6/2002	Sun
5,978,713	A	11/1999	Prutchi et al.	6,409,674	B1	6/2002	Brockway et al.
5,987,352	A	11/1999	Klein et al.	6,411,848	B2	6/2002	Kramer et al.
5,991,660	A	11/1999	Goyal	6,415,184	B1	7/2002	Ishikawa et al.
5,991,661	A	11/1999	Park et al.	6,424,865	B1	7/2002	Ding
5,999,848	A	12/1999	Gord et al.	6,434,429	B1	8/2002	Kraus et al.
5,999,857	A	12/1999	Weijand et al.	6,438,410	B2	8/2002	Hsu et al.
6,016,445	A	1/2000	Baura	6,438,417	B1	8/2002	Rockwell et al.
6,026,320	A	2/2000	Carlson et al.	6,438,421	B1	8/2002	Stahmann et al.
6,029,085	A	2/2000	Olson et al.	6,440,066	B1	8/2002	Bardy
6,041,250	A	3/2000	DePinto	6,441,747	B1	8/2002	Khair et al.
6,044,298	A	3/2000	Salo et al.	6,442,426	B1	8/2002	Kroll
6,044,300	A	3/2000	Gray	6,442,432	B2	8/2002	Lee
6,051,017	A	4/2000	Loeb et al.	6,443,891	B1	9/2002	Grevious
6,055,454	A	4/2000	Heemels	6,445,953	B1	9/2002	Bulkes et al.
6,073,050	A	6/2000	Griffith	6,453,200	B1	9/2002	Koslar
6,076,016	A	6/2000	Feierbach	6,459,929	B1	10/2002	Hopper et al.
6,077,236	A	6/2000	Cunningham	6,470,215	B1	10/2002	Kraus et al.
6,080,187	A	6/2000	Alt et al.	6,471,645	B1	10/2002	Warkentin et al.
6,083,248	A	7/2000	Thompson	6,480,745	B2	11/2002	Nelson et al.
6,106,551	A	8/2000	Crossett et al.	6,487,443	B2	11/2002	Olson et al.
6,115,636	A	9/2000	Ryan	6,490,487	B1	12/2002	Kraus et al.
6,128,526	A	10/2000	Stadler et al.	6,498,951	B1	12/2002	Larson et al.
6,141,581	A	10/2000	Olson et al.	6,507,755	B1	1/2003	Gozani et al.
6,141,588	A	10/2000	Cox et al.	6,507,759	B1	1/2003	Prutchi et al.
6,141,592	A	10/2000	Pauly	6,512,940	B1	1/2003	Brabec et al.
6,144,879	A	11/2000	Gray	6,522,915	B1	2/2003	Ceballos et al.
6,162,195	A	12/2000	Igo et al.	6,526,311	B2	2/2003	Begemann
6,164,284	A	12/2000	Schulman et al.	6,539,253	B2	3/2003	Thompson et al.
6,167,310	A	12/2000	Grevious	6,542,775	B2	4/2003	Ding et al.
6,175,764	B1	1/2001	Loeb et al.	6,553,258	B2	4/2003	Stahmann et al.
6,181,965	B1	1/2001	Loeb et al.	6,561,975	B1	5/2003	Pool et al.
6,185,452	B1	2/2001	Schulman et al.	6,564,807	B1	5/2003	Schulman et al.
6,185,455	B1	2/2001	Loeb et al.	6,574,506	B2	6/2003	Kramer et al.
6,198,972	B1	3/2001	Hartlaub et al.	6,580,947	B1	6/2003	Thompson
6,201,993	B1	3/2001	Kruse et al.	6,584,351	B1	6/2003	Ekwall
6,208,894	B1	3/2001	Schulman et al.	6,584,352	B2	6/2003	Combs et al.
6,208,900	B1	3/2001	Ecker et al.	6,592,518	B2	7/2003	Denker et al.
6,208,901	B1	3/2001	Hartung	6,597,948	B1	7/2003	Rockwell et al.
6,211,799	B1	4/2001	Post et al.	6,597,951	B2	7/2003	Kramer et al.
6,214,032	B1	4/2001	Loeb et al.	6,622,046	B2	9/2003	Fraley et al.
6,221,011	B1	4/2001	Bardy	6,628,985	B2	9/2003	Sweeney et al.
6,240,316	B1	5/2001	Richmond et al.	6,628,989	B1	9/2003	Penner et al.
6,240,317	B1	5/2001	Villaseca et al.	6,647,292	B1	11/2003	Bardy et al.
6,256,534	B1	7/2001	Dahl	6,654,638	B1	11/2003	Sweeney
6,259,947	B1	7/2001	Olson et al.	6,662,050	B2	12/2003	Olson
6,266,558	B1	7/2001	Gozani et al.	6,666,844	B1	12/2003	Igo et al.
6,266,567	B1	7/2001	Ishikawa et al.	6,689,117	B2	2/2004	Sweeney et al.
6,270,457	B1	8/2001	Bardy	6,690,959	B2	2/2004	Thompson
6,272,377	B1	8/2001	Sweeney et al.	6,694,189	B2	2/2004	Begemann
6,273,856	B1	8/2001	Sun et al.	6,704,602	B2	3/2004	Berg et al.
6,277,072	B1	8/2001	Bardy	6,718,212	B2	4/2004	Parry et al.
6,280,380	B1	8/2001	Bardy	6,721,597	B1	4/2004	Bardy et al.
6,285,907	B1	9/2001	Kramer et al.	6,733,485	B1	5/2004	Whitehurst et al.
				6,735,474	B1	5/2004	Loeb et al.
				6,735,475	B1	5/2004	Whitehurst et al.
				6,738,670	B1	5/2004	Almendinger et al.
				6,738,672	B2	5/2004	Schulman et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,746,797 B2	6/2004	Benson et al.	7,200,439 B2	4/2007	Zdeblick et al.
6,749,566 B2	6/2004	Russ	7,203,548 B2	4/2007	Whitehurst et al.
6,758,810 B2	7/2004	Lebel et al.	7,206,423 B1	4/2007	Feng et al.
6,763,269 B2	7/2004	Cox	7,209,785 B2	4/2007	Kim et al.
6,764,446 B2	7/2004	Wolinsky et al.	7,209,790 B2	4/2007	Thompson et al.
6,778,860 B2	8/2004	Ostroff et al.	7,211,884 B1	5/2007	Davis et al.
6,788,971 B1	9/2004	Sloman et al.	7,212,863 B2	5/2007	Strandberg
6,788,974 B2	9/2004	Bardy et al.	7,212,871 B1	5/2007	Morgan
6,788,975 B1	9/2004	Whitehurst et al.	7,214,189 B2	5/2007	Zdeblick
6,804,558 B2	10/2004	Haller et al.	7,226,440 B2	6/2007	Gelfand et al.
6,804,561 B2	10/2004	Stover	7,228,183 B2	6/2007	Sun et al.
6,807,442 B1	10/2004	Myklebust et al.	7,236,821 B2	6/2007	Cates et al.
6,847,844 B2	1/2005	Sun et al.	7,236,829 B1	6/2007	Farazi et al.
6,871,095 B2	3/2005	Stahmann et al.	7,242,981 B2	7/2007	Ginggen
6,871,099 B1	3/2005	Whitehurst et al.	7,254,448 B2	8/2007	Almendinger et al.
6,878,112 B2	4/2005	Linberg et al.	7,260,436 B2	8/2007	Kilgore et al.
6,885,889 B2	4/2005	Chinchoy	7,270,669 B1	9/2007	Sra
6,892,094 B2	5/2005	Ousdigian et al.	7,272,448 B1	9/2007	Morgan et al.
6,897,788 B2	5/2005	Khair et al.	7,277,755 B1	10/2007	Falkenberg et al.
6,901,292 B2	5/2005	Hrdlicka et al.	7,280,872 B1	10/2007	Mosesov et al.
6,904,315 B2	6/2005	Panken et al.	7,283,873 B1	10/2007	Park et al.
6,907,285 B2	6/2005	Denker et al.	7,283,874 B2	10/2007	Penner
6,917,833 B2	7/2005	Denker et al.	7,286,883 B2	10/2007	Schulman et al.
6,922,592 B2	7/2005	Thompson et al.	7,288,096 B2	10/2007	Chin
6,925,328 B2	8/2005	Foster et al.	7,289,847 B1	10/2007	Gill et al.
6,931,282 B2	8/2005	Esler	7,289,852 B2	10/2007	Helfinstine et al.
6,934,585 B1	8/2005	Schloss et al.	7,289,853 B1	10/2007	Campbell et al.
6,937,906 B2	8/2005	Terry et al.	7,289,855 B2	10/2007	Nghiem et al.
6,941,171 B2	9/2005	Mann et al.	7,292,890 B2	11/2007	Whitehurst et al.
6,947,782 B2	9/2005	Schulman et al.	7,294,108 B1	11/2007	Bornzin et al.
6,957,107 B2	10/2005	Rogers et al.	7,295,879 B2	11/2007	Denker et al.
6,978,176 B2	12/2005	Lattouf	7,302,294 B2	11/2007	Kamath et al.
6,985,773 B2	1/2006	Von Arx et al.	7,305,266 B1	12/2007	Kroll
6,990,375 B2	1/2006	Kloss et al.	7,310,556 B2	12/2007	Bulkes
7,001,366 B2	2/2006	Ballard	7,319,905 B1	1/2008	Morgan et al.
7,003,350 B2	2/2006	Denker et al.	7,321,798 B2	1/2008	Muhlenberg et al.
7,006,864 B2	2/2006	Echt et al.	7,330,756 B2	2/2008	Marnfeldt
7,013,178 B2	3/2006	Reinke et al.	7,333,853 B2	2/2008	Mazar et al.
7,024,248 B2	4/2006	Penner et al.	7,336,994 B2	2/2008	Hettrick et al.
7,027,871 B2	4/2006	Burnes et al.	7,343,204 B2	3/2008	Schulman et al.
7,047,074 B2	5/2006	Connelly et al.	7,347,819 B2	3/2008	Lebel et al.
7,050,849 B2	5/2006	Echt et al.	7,351,921 B1	4/2008	Haller et al.
7,054,692 B1	5/2006	Whitehurst et al.	7,363,082 B2	4/2008	Ransbury et al.
7,060,031 B2	6/2006	Webb et al.	7,366,572 B2	4/2008	Heruth et al.
7,063,693 B2	6/2006	Guenst	7,373,207 B2	5/2008	Lattouf
7,076,283 B2	7/2006	Cho et al.	7,384,403 B2	6/2008	Sherman
7,082,328 B2	7/2006	Funke	7,386,342 B1	6/2008	Falkenberg et al.
7,082,336 B2	7/2006	Ransbury et al.	7,392,090 B2	6/2008	Sweeney et al.
7,085,606 B2	8/2006	Flach et al.	7,406,105 B2	7/2008	DelMain et al.
7,092,758 B2	8/2006	Sun et al.	7,406,349 B2	7/2008	Seeberger et al.
7,103,408 B2	9/2006	Haller et al.	7,410,497 B2	8/2008	Hastings et al.
7,110,824 B2	9/2006	Amundson et al.	7,425,200 B2	9/2008	Brockway et al.
7,114,502 B2	10/2006	Schulman et al.	7,428,438 B2	9/2008	Parramon et al.
7,120,504 B2	10/2006	Osypka	7,433,739 B1	10/2008	Salys et al.
7,120,992 B2	10/2006	He et al.	7,437,193 B2	10/2008	Parramon et al.
7,130,681 B2	10/2006	Gebhardt et al.	7,444,180 B2	10/2008	Kuzma et al.
7,132,173 B2	11/2006	Daulton	7,450,996 B2	11/2008	MacDonald et al.
7,139,613 B2	11/2006	Reinke et al.	7,450,998 B2	11/2008	Zilberman et al.
7,142,912 B2	11/2006	Wagner et al.	7,493,172 B2	2/2009	Whitehurst et al.
7,146,225 B2	12/2006	Guenst et al.	7,496,409 B2	2/2009	Greenhut et al.
7,146,226 B2	12/2006	Lau et al.	7,496,410 B2	2/2009	Heil
7,149,581 B2	12/2006	Goedeke	7,502,652 B2	3/2009	Gaunt et al.
7,149,588 B2	12/2006	Lau et al.	7,512,448 B2	3/2009	Malick et al.
7,158,839 B2	1/2007	Lau	7,513,257 B2	4/2009	Schulman et al.
7,162,307 B2	1/2007	Patrias	7,515,969 B2	4/2009	Tockman et al.
7,164,952 B2	1/2007	Lau et al.	7,519,421 B2	4/2009	Denker et al.
7,167,751 B1	1/2007	Whitehurst et al.	7,519,424 B2	4/2009	Dennis et al.
7,177,698 B2	2/2007	Klosterman et al.	7,526,342 B2	4/2009	Chin et al.
7,177,700 B1	2/2007	Cox	7,529,589 B2	5/2009	Williams et al.
7,181,505 B2	2/2007	Haller et al.	7,532,932 B2	5/2009	Denker et al.
7,184,830 B2	2/2007	Echt et al.	7,532,933 B2	5/2009	Hastings et al.
7,186,214 B2	3/2007	Ness	7,535,296 B2	5/2009	Bulkes et al.
7,191,015 B2	3/2007	Lamson et al.	7,536,222 B2	5/2009	Bardy et al.
7,198,603 B2	4/2007	Penner et al.	7,536,224 B2	5/2009	Ritscher et al.
7,200,437 B1	4/2007	Nabutovsky et al.	7,539,541 B2	5/2009	Quiles et al.
			7,544,197 B2	6/2009	Kelsch et al.
			7,555,345 B2	6/2009	Wahlstrand et al.
			7,558,631 B2	7/2009	Cowan et al.
			7,561,915 B1	7/2009	Cooke et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,565,195 B1	7/2009	Kroll et al.	7,890,173 B2	2/2011	Brisken et al.
7,584,002 B2	9/2009	Burnes et al.	7,890,181 B2	2/2011	Denzene et al.
7,587,241 B2	9/2009	Parramon et al.	7,890,192 B1	2/2011	Kelsch et al.
7,590,455 B2	9/2009	Heruth et al.	7,894,885 B2	2/2011	Bartal et al.
7,606,621 B2	10/2009	Brisken et al.	7,894,894 B2	2/2011	Stadler et al.
7,610,088 B2	10/2009	Chinchoy	7,894,907 B2	2/2011	Cowan et al.
7,610,092 B2	10/2009	Cowan et al.	7,894,910 B2	2/2011	Cowan et al.
7,610,099 B2	10/2009	Almendinger et al.	7,894,915 B1	2/2011	Chitre et al.
7,610,104 B2	10/2009	Kaplan et al.	7,899,537 B1	3/2011	Kroll et al.
7,616,990 B2	11/2009	Chavan et al.	7,899,541 B2	3/2011	Cowan et al.
7,616,991 B2	11/2009	Mann et al.	7,899,542 B2	3/2011	Cowan et al.
7,616,992 B2	11/2009	Dennis et al.	7,899,554 B2	3/2011	Williams et al.
7,617,001 B2	11/2009	Penner et al.	7,901,360 B1	3/2011	Yang et al.
7,617,007 B2	11/2009	Williams et al.	7,904,167 B2	3/2011	Klosterman et al.
7,627,371 B2	12/2009	Wang et al.	7,904,170 B2	3/2011	Harding
7,627,376 B2	12/2009	Dennis et al.	7,907,993 B2	3/2011	Ghanem et al.
7,627,383 B2	12/2009	Haller et al.	7,920,928 B1	4/2011	Fang et al.
7,630,767 B1	12/2009	Poore et al.	7,925,343 B1	4/2011	Min et al.
7,634,313 B1	12/2009	Kroll et al.	7,930,022 B2	4/2011	Zhang et al.
7,637,867 B2	12/2009	Zdeblick	7,930,031 B2	4/2011	Penner
7,640,060 B2	12/2009	Zdeblick	7,930,040 B1	4/2011	Kelsch et al.
7,640,061 B2	12/2009	He et al.	7,937,135 B2	5/2011	Ghanem et al.
7,647,109 B2	1/2010	Hastings et al.	7,937,148 B2	5/2011	Jacobson
7,650,186 B2	1/2010	Hastings et al.	7,937,161 B2	5/2011	Hastings et al.
7,657,311 B2	2/2010	Bardy et al.	7,941,214 B2	5/2011	Kleckner et al.
7,668,596 B2	2/2010	Von Arx et al.	7,945,333 B2	5/2011	Jacobson
7,682,316 B2	3/2010	Anderson et al.	7,946,997 B2	5/2011	Hübinette
7,689,283 B1	3/2010	Schecter	7,949,404 B2	5/2011	Hill
7,691,047 B2	4/2010	Ferrari	7,949,405 B2	5/2011	Feher
7,702,392 B2	4/2010	Echt et al.	7,953,486 B2	5/2011	Daum et al.
7,706,892 B2	4/2010	Colvin et al.	7,953,493 B2	5/2011	Fowler et al.
7,713,194 B2	5/2010	Zdeblick	7,957,805 B2	6/2011	He
7,713,195 B2	5/2010	Zdeblick	7,962,202 B2	6/2011	Bhunia
7,729,783 B2	6/2010	Michels et al.	7,974,702 B1	7/2011	Fain et al.
7,734,333 B2	6/2010	Ghanem et al.	7,979,126 B2	7/2011	Payne et al.
7,734,343 B2	6/2010	Ransbury et al.	7,979,136 B2	7/2011	Young et al.
7,738,958 B2	6/2010	Zdeblick et al.	7,983,753 B2	7/2011	Severin
7,738,964 B2	6/2010	Von Arx et al.	7,991,467 B2	8/2011	Markowitz et al.
7,742,812 B2	6/2010	Ghanem et al.	7,991,471 B2	8/2011	Ghanem et al.
7,742,816 B2	6/2010	Masoud et al.	7,996,087 B2	8/2011	Cowan et al.
7,742,822 B2	6/2010	Masoud et al.	7,996,097 B2	8/2011	DiBernardo et al.
7,743,151 B2	6/2010	Vallapureddy et al.	8,000,791 B2	8/2011	Sunagawa et al.
7,747,335 B2	6/2010	Williams	8,000,807 B2	8/2011	Morris et al.
7,751,881 B2	7/2010	Cowan et al.	8,001,975 B2	8/2011	DiSilvestro et al.
7,758,521 B2	7/2010	Morris et al.	8,002,700 B2	8/2011	Ferek-Petric et al.
7,761,150 B2	7/2010	Ghanem et al.	8,010,209 B2	8/2011	Jacobson
7,761,164 B2	7/2010	Verhoef et al.	8,019,419 B1	9/2011	Panescu et al.
7,765,001 B2	7/2010	Echt et al.	8,019,434 B2	9/2011	Quiles et al.
7,766,216 B2	8/2010	Daulton	8,027,727 B2	9/2011	Freeberg
7,769,452 B2	8/2010	Ghanem et al.	8,027,729 B2	9/2011	Sunagawa et al.
7,771,838 B1	8/2010	He et al.	8,032,219 B2	10/2011	Neumann et al.
7,781,683 B2	8/2010	Haller et al.	8,032,227 B2	10/2011	Parramon et al.
7,783,362 B2	8/2010	Whitehurst et al.	8,036,743 B2	10/2011	Savage et al.
7,792,588 B2	9/2010	Harding	8,046,079 B2	10/2011	Bange et al.
7,797,059 B1	9/2010	Bornzin et al.	8,046,080 B2	10/2011	Von Arx et al.
7,801,596 B2	9/2010	Fischell et al.	8,050,297 B2	11/2011	DelMain et al.
7,809,438 B2	10/2010	Echt et al.	8,050,759 B2	11/2011	Stegemann et al.
7,822,480 B2	10/2010	Park et al.	8,050,774 B2	11/2011	Kveen et al.
7,826,903 B2	11/2010	Denker et al.	8,055,345 B2	11/2011	Li et al.
7,840,281 B2	11/2010	Kveen et al.	8,055,350 B2	11/2011	Roberts
7,840,282 B2	11/2010	Williams et al.	8,060,212 B1	11/2011	Rios et al.
7,844,331 B2	11/2010	Li et al.	8,065,018 B2	11/2011	Haubrich et al.
7,844,348 B2	11/2010	Swoyer et al.	8,073,542 B2	12/2011	Doerr
7,846,088 B2	12/2010	Ness	8,078,278 B2	12/2011	Penner
7,848,815 B2	12/2010	Brisken et al.	8,078,279 B2	12/2011	Dennis et al.
7,848,823 B2	12/2010	Drasler et al.	8,078,283 B2	12/2011	Cowan et al.
7,860,455 B2	12/2010	Fukumoto et al.	8,095,123 B2	1/2012	Gray
7,860,564 B2	12/2010	Root et al.	8,102,789 B2	1/2012	Rosar et al.
7,860,570 B2	12/2010	Whitehurst et al.	8,103,344 B2	1/2012	Bjrling
7,871,433 B2	1/2011	Lattouf	8,103,359 B2	1/2012	Reddy
7,877,136 B1	1/2011	Moffitt et al.	8,103,361 B2	1/2012	Moser
7,877,142 B2	1/2011	Moaddeb et al.	8,112,148 B2	2/2012	Giftakis et al.
7,881,786 B2	2/2011	Jackson	8,114,021 B2	2/2012	Robertson et al.
7,881,798 B2	2/2011	Miesel et al.	8,116,883 B2	2/2012	Williams et al.
7,881,810 B1	2/2011	Chitre et al.	8,121,680 B2	2/2012	Falkenberg et al.
			8,123,684 B2	2/2012	Zdeblick
			8,126,545 B2	2/2012	Flach et al.
			8,126,561 B2	2/2012	Chavan et al.
			8,311,627 B2	2/2012	Root et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,127,424 B2	3/2012	Haller et al.	8,447,412 B2	5/2013	Dal Molin et al.
8,131,334 B2	3/2012	Lu et al.	8,452,413 B2	5/2013	Young et al.
8,140,161 B2	3/2012	Willerton et al.	8,457,740 B2	6/2013	Osche
8,150,521 B2	4/2012	Crowley et al.	8,457,742 B2	6/2013	Jacobson
8,160,672 B2	4/2012	Kim et al.	8,457,744 B2	6/2013	Janzig et al.
8,160,702 B2	4/2012	Mann et al.	8,457,761 B2	6/2013	Wariar
8,160,704 B2	4/2012	Freeberg	8,478,407 B2	7/2013	Demmer et al.
8,165,694 B2	4/2012	Carbanaru et al.	8,478,408 B2	7/2013	Hastings et al.
8,165,696 B2	4/2012	McClure et al.	8,478,431 B2	7/2013	Griswold et al.
8,175,715 B1	5/2012	Cox	8,489,205 B2	7/2013	Stotts et al.
8,180,451 B2	5/2012	Hickman et al.	8,494,631 B2	7/2013	Zhang et al.
8,185,212 B2	5/2012	Carbanaru et al.	8,494,632 B2	7/2013	Sun et al.
8,185,213 B2	5/2012	Kveen et al.	8,494,637 B2	7/2013	Cowan et al.
8,187,161 B2	5/2012	Li et al.	8,494,642 B2	7/2013	Cowan et al.
8,195,293 B2	6/2012	Limousin et al.	8,494,644 B2	7/2013	Cowan et al.
8,204,595 B2	6/2012	Pianca et al.	8,504,156 B2	8/2013	Bonner et al.
8,204,605 B2	6/2012	Hastings et al.	8,509,910 B2	8/2013	Sowder et al.
8,209,014 B2	6/2012	Doerr	8,515,559 B2	8/2013	Roberts et al.
8,214,043 B2	7/2012	Matos	8,525,340 B2	9/2013	Eckhardt et al.
8,224,244 B2	7/2012	Kim et al.	8,527,068 B2	9/2013	Ostroff
8,224,449 B2	7/2012	Carbanaru et al.	8,532,790 B2	9/2013	Griswold
8,229,556 B2	7/2012	Li	8,538,526 B2	9/2013	Stahmann et al.
8,233,985 B2	7/2012	Bulkes et al.	8,541,131 B2	9/2013	Lund et al.
8,239,045 B2	8/2012	Ransbury et al.	8,543,190 B2	9/2013	Wasson et al.
8,240,780 B1	8/2012	Klimes	8,543,204 B2	9/2013	Demmer et al.
8,262,578 B1	9/2012	Bharmi et al.	8,543,205 B2	9/2013	Ostroff
8,265,748 B2	9/2012	Liu et al.	8,543,216 B2	9/2013	Carbanaru et al.
8,265,757 B2	9/2012	Mass et al.	8,547,248 B2	10/2013	Zdeblick et al.
8,280,521 B2	10/2012	Haubrich et al.	8,548,605 B2	10/2013	Ollivier
8,285,387 B2	10/2012	Utsi et al.	8,554,333 B2	10/2013	Wu et al.
8,290,577 B2	10/2012	Brooks et al.	8,560,892 B2	10/2013	Nicholes
8,290,598 B2	10/2012	Boon et al.	8,565,882 B2	10/2013	Matos
8,290,600 B2	10/2012	Hastings et al.	8,565,897 B2	10/2013	Regnier et al.
8,295,939 B2	10/2012	Jacobson	8,571,678 B2	10/2013	Wang
8,301,242 B2	10/2012	Root et al.	8,577,327 B2	11/2013	Makdissi et al.
8,301,254 B2	10/2012	Mosesov et al.	8,588,926 B2	11/2013	Moore et al.
8,301,262 B2	10/2012	Mi et al.	8,612,002 B2	12/2013	Faltys et al.
8,315,701 B2	11/2012	Cowan et al.	8,615,310 B2	12/2013	Khairkhahan et al.
8,315,708 B2	11/2012	Berthelsdorf et al.	8,626,280 B2	1/2014	Allavatam et al.
8,321,021 B2	11/2012	Kisker et al.	8,626,294 B2	1/2014	Sheldon et al.
8,321,036 B2	11/2012	Brockway et al.	8,634,908 B2	1/2014	Cowan
8,332,036 B2	12/2012	Hastings et al.	8,634,912 B2	1/2014	Bornzin et al.
8,335,563 B2	12/2012	Stessman	8,634,919 B1	1/2014	Hou et al.
8,335,568 B2	12/2012	Heruth et al.	8,639,335 B2	1/2014	Peichel et al.
8,340,750 B2	12/2012	Prakash et al.	8,644,922 B2	2/2014	Root et al.
8,340,780 B2	12/2012	Hastings et al.	8,644,934 B2	2/2014	Hastings et al.
8,352,025 B2	1/2013	Jacobson	8,649,859 B2	2/2014	Smith et al.
8,352,028 B2	1/2013	Wenger	8,660,660 B2	2/2014	Dai et al.
8,352,038 B2	1/2013	Mao et al.	8,670,842 B1	3/2014	Bornzin et al.
8,359,098 B2	1/2013	Lund et al.	8,676,319 B2	3/2014	Knoll
8,364,261 B2	1/2013	Stubbs et al.	8,676,335 B2	3/2014	Katoozi et al.
8,364,267 B2	1/2013	Schleicher et al.	8,700,173 B2	4/2014	Edlund
8,364,276 B2	1/2013	Willis	8,700,181 B2	4/2014	Bornzin et al.
8,364,278 B2	1/2013	Pianca et al.	8,705,599 B2	4/2014	dal Molin et al.
8,364,280 B2	1/2013	Marnfeldt et al.	8,718,766 B2	5/2014	Wahlberg
8,368,051 B2	2/2013	Ting et al.	8,718,773 B2	5/2014	Willis et al.
8,369,959 B2	2/2013	Meskens	8,725,260 B2	5/2014	Shuros et al.
8,369,962 B2	2/2013	Abrahamson	8,738,133 B2	5/2014	Shuros et al.
8,374,696 B2	2/2013	Sanchez et al.	8,738,147 B2	5/2014	Hastings et al.
8,380,320 B2	2/2013	Spital	8,744,555 B2	6/2014	Allavatam et al.
8,386,051 B2	2/2013	Rys	8,744,572 B1	6/2014	Greenhut et al.
8,391,981 B2	3/2013	Mosesov	8,747,314 B2	6/2014	Stahmann et al.
8,391,990 B2	3/2013	Smith et al.	8,755,884 B2	6/2014	Demmer et al.
8,406,874 B2	3/2013	Liu et al.	8,758,365 B2	6/2014	Bonner et al.
8,406,879 B2	3/2013	Shuros et al.	8,768,483 B2	7/2014	Schmitt et al.
8,406,886 B2	3/2013	Gaunt et al.	8,774,572 B2	7/2014	Hamamoto
8,412,323 B2	4/2013	Bauer	8,781,605 B2	7/2014	Bornzin et al.
8,412,352 B2	4/2013	Griswold et al.	8,788,035 B2	7/2014	Jacobson
8,417,340 B2	4/2013	Goossen	8,788,053 B2	7/2014	Jacobson
8,417,341 B2	4/2013	Freeberg	8,798,740 B2	8/2014	Samade et al.
8,423,149 B2	4/2013	Hennig	8,798,745 B2	8/2014	Jacobson
8,428,722 B2	4/2013	Verhoef et al.	8,798,762 B2	8/2014	Fain et al.
8,433,402 B2	4/2013	Ruben et al.	8,798,770 B2	8/2014	Reddy
8,433,409 B2	4/2013	Johnson et al.	8,805,505 B1	8/2014	Roberts
8,433,420 B2	4/2013	Bange et al.	8,805,528 B2	8/2014	Corndorf
			8,812,109 B2	8/2014	Blomqvist et al.
			8,818,504 B2	8/2014	Bodner et al.
			8,827,913 B2	9/2014	Havel et al.
			8,831,747 B1	9/2014	Min et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,855,789 B2	10/2014	Jacobson	9,511,236 B2	12/2016	Varady et al.
8,868,186 B2	10/2014	Kroll	9,511,237 B2	12/2016	Deterre et al.
8,886,339 B2	11/2014	Faltys et al.	9,522,276 B2	12/2016	Shen et al.
8,903,473 B2	12/2014	Rogers et al.	9,522,280 B2	12/2016	Fishier et al.
8,903,500 B2	12/2014	Smith et al.	9,526,522 B2	12/2016	Wood et al.
8,903,513 B2	12/2014	Ollivier	9,526,891 B2	12/2016	Eggen et al.
8,909,336 B2	12/2014	Navarro-Paredes et al.	9,526,909 B2	12/2016	Stahmann et al.
8,914,131 B2	12/2014	Bornzin et al.	9,533,163 B2	1/2017	Klimovitch et al.
8,923,795 B2	12/2014	Makdissi et al.	9,561,382 B2	2/2017	Persson et al.
8,923,963 B2	12/2014	Bonner et al.	9,566,012 B2	2/2017	Greenhut et al.
8,938,300 B2	1/2015	Rosero	9,636,511 B2	5/2017	Carney et al.
8,942,806 B2	1/2015	Sheldon et al.	9,669,223 B2	6/2017	Auricchio et al.
8,954,147 B2	2/2015	Arcot-Krishnamurthy et al.	9,687,654 B2	6/2017	Sheldon et al.
8,958,892 B2	2/2015	Khairkhahan et al.	9,687,655 B2	6/2017	Pertijs et al.
8,977,358 B2	3/2015	Ewert et al.	9,687,659 B2	6/2017	Von Arx et al.
8,989,873 B2	3/2015	Locsin	9,694,186 B2	7/2017	Carney et al.
8,996,101 B2	3/2015	Zhang et al.	9,782,594 B2	10/2017	Stahmann et al.
8,996,109 B2 *	3/2015	Karst A61N 1/36592 607/25	9,782,601 B2	10/2017	Ludwig
9,002,467 B2	4/2015	Smith et al.	9,789,317 B2	10/2017	Greenhut et al.
9,008,776 B2	4/2015	Cowan et al.	9,789,319 B2	10/2017	Sambelashvili
9,008,777 B2	4/2015	Dianaty et al.	9,808,617 B2	11/2017	Ostroff et al.
9,014,818 B2	4/2015	Deterre et al.	9,808,628 B2	11/2017	Sheldon et al.
9,017,341 B2	4/2015	Bornzin et al.	9,808,631 B2	11/2017	Maile et al.
9,020,611 B2	4/2015	Khairkhahan et al.	9,808,632 B2	11/2017	Reinke et al.
9,037,262 B2	5/2015	Regnier et al.	9,808,633 B2	11/2017	Bonner et al.
9,042,984 B2	5/2015	Demmer et al.	9,808,637 B2	11/2017	Sharma et al.
9,072,911 B2	7/2015	Hastings et al.	9,855,414 B2	1/2018	Marshall et al.
9,072,913 B2	7/2015	Jacobson	9,855,430 B2	1/2018	Ghosh et al.
9,155,882 B2	10/2015	Grubac et al.	9,855,435 B2	1/2018	Sahabi et al.
9,168,372 B2	10/2015	Fain	9,861,815 B2	1/2018	Tran et al.
9,168,380 B1	10/2015	Greenhut et al.	2002/0032470 A1	3/2002	Linberg
9,168,383 B2	10/2015	Jacobson et al.	2002/0035376 A1	3/2002	Bardy et al.
9,180,285 B2	11/2015	Moore et al.	2002/0035377 A1	3/2002	Bardy et al.
9,192,774 B2	11/2015	Jacobson	2002/0035378 A1	3/2002	Bardy et al.
9,205,225 B2	12/2015	Khairkhahan et al.	2002/0035380 A1	3/2002	Rissmann et al.
9,216,285 B1	12/2015	Boling et al.	2002/0035381 A1	3/2002	Bardy et al.
9,216,293 B2	12/2015	Berthiaume et al.	2002/0042629 A1	4/2002	Bardy et al.
9,216,298 B2	12/2015	Jacobson	2002/0042630 A1	4/2002	Bardy et al.
9,227,077 B2	1/2016	Jacobson	2002/0042634 A1	4/2002	Bardy et al.
9,238,145 B2	1/2016	Wenzel et al.	2002/0049475 A1	4/2002	Bardy et al.
9,242,102 B2	1/2016	Khairkhahan et al.	2002/0052636 A1	5/2002	Bardy et al.
9,242,113 B2	1/2016	Smith et al.	2002/0068958 A1	6/2002	Bardy et al.
9,248,300 B2	2/2016	Rys et al.	2002/0072773 A1	6/2002	Bardy et al.
9,265,436 B2	2/2016	Min et al.	2002/0082665 A1	6/2002	Haller et al.
9,265,962 B2	2/2016	Dianaty et al.	2002/0091414 A1	7/2002	Bardy et al.
9,272,155 B2	3/2016	Ostroff	2002/0095196 A1	7/2002	Linberg
9,278,218 B2	3/2016	Karst et al.	2002/0099423 A1	7/2002	Berg et al.
9,278,229 B1	3/2016	Reinke et al.	2002/0103510 A1	8/2002	Bardy et al.
9,283,381 B2	3/2016	Grubac et al.	2002/0107545 A1	8/2002	Rissmann et al.
9,283,382 B2	3/2016	Berthiaume et al.	2002/0107546 A1	8/2002	Ostroff et al.
9,289,612 B1	3/2016	Sambelashvili et al.	2002/0107547 A1	8/2002	Edinger et al.
9,302,115 B2	4/2016	Molin et al.	2002/0107548 A1	8/2002	Bardy et al.
9,333,364 B2	5/2016	Echt et al.	2002/0107549 A1	8/2002	Bardy et al.
9,358,387 B2	6/2016	Suwito et al.	2002/0107559 A1	8/2002	Sanders et al.
9,358,400 B2	6/2016	Jacobson	2002/0120299 A1	8/2002	Ostroff et al.
9,364,675 B2	6/2016	Deterre et al.	2002/0173830 A1	11/2002	Starkweather et al.
9,370,663 B2	6/2016	Moulder	2002/0193846 A1	12/2002	Pool et al.
9,375,580 B2	6/2016	Bonner et al.	2003/0009203 A1	1/2003	Lebel et al.
9,375,581 B2	6/2016	Baru et al.	2003/0028082 A1	2/2003	Thompson
9,381,365 B2	7/2016	Kibler et al.	2003/0040779 A1	2/2003	Engmark et al.
9,393,424 B2	7/2016	Demmer et al.	2003/0041866 A1	3/2003	Linberg et al.
9,393,436 B2	7/2016	Doerr	2003/0045805 A1	3/2003	Sheldon et al.
9,399,139 B2	7/2016	Demmer et al.	2003/0088278 A1	5/2003	Bardy et al.
9,399,140 B2	7/2016	Cho et al.	2003/0097153 A1	5/2003	Bardy et al.
9,409,033 B2	8/2016	Jacobson	2003/0105497 A1	6/2003	Zhu et al.
9,427,594 B1	8/2016	Bornzin et al.	2003/0114905 A1	6/2003	Kuzma
9,433,368 B2	9/2016	Stahmann et al.	2003/0114908 A1	6/2003	Flach
9,433,780 B2	9/2016	Régnier et al.	2003/0144701 A1	7/2003	Mehra et al.
9,457,193 B2	10/2016	Klimovitch et al.	2003/0144704 A1	7/2003	Terry et al.
9,492,668 B2	11/2016	Sheldon et al.	2003/0187460 A1	10/2003	Chin et al.
9,492,669 B2	11/2016	Demmer et al.	2003/0187461 A1	10/2003	Chin
9,492,674 B2	11/2016	Schmidt et al.	2003/0204212 A1	10/2003	Burnes et al.
9,492,677 B2	11/2016	Greenhut et al.	2004/0015204 A1	1/2004	Whitehurst et al.
9,511,233 B2	12/2016	Sambelashvili	2004/0024435 A1	2/2004	Leckrone et al.
			2004/0068302 A1	4/2004	Rodgers et al.
			2004/0073267 A1	4/2004	Holzer
			2004/0087938 A1	5/2004	Leckrone et al.
			2004/0088012 A1	5/2004	Kroll et al.
			2004/0088035 A1	5/2004	Guenst et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2009/0024180	A1	1/2009	Kisker et al.	2011/0077721	A1	3/2011	Whitehurst et al.
2009/0036941	A1	2/2009	Corbucci	2011/0112600	A1	5/2011	Cowan et al.
2009/0048583	A1	2/2009	Williams et al.	2011/0118588	A1	5/2011	Komblau et al.
2009/0048646	A1	2/2009	Katoozi et al.	2011/0118810	A1	5/2011	Cowan et al.
2009/0062895	A1	3/2009	Stahmann et al.	2011/0137187	A1	6/2011	Yang et al.
2009/0082827	A1	3/2009	Kveen et al.	2011/0137378	A1	6/2011	Klosterman et al.
2009/0082828	A1	3/2009	Ostroff	2011/0144720	A1	6/2011	Cowan et al.
2009/0088813	A1	4/2009	Brockway et al.	2011/0152970	A1	6/2011	Jollota et al.
2009/0105779	A1	4/2009	Moore et al.	2011/0160558	A1	6/2011	Rassatt et al.
2009/0131907	A1	5/2009	Chin et al.	2011/0160565	A1	6/2011	Stubbs et al.
2009/0135886	A1	5/2009	Robertson et al.	2011/0160787	A1	6/2011	Greenhut et al.
2009/0143835	A1	6/2009	Pastore et al.	2011/0160792	A1	6/2011	Fishel
2009/0157146	A1	6/2009	Linder et al.	2011/0160801	A1	6/2011	Markowitz et al.
2009/0171408	A1	7/2009	Solem	2011/0160806	A1	6/2011	Lyden et al.
2009/0171414	A1	7/2009	Kelly et al.	2011/0166620	A1	7/2011	Cowan et al.
2009/0192570	A1	7/2009	Jaax et al.	2011/0166621	A1	7/2011	Cowan et al.
2009/0198293	A1	8/2009	Cauller et al.	2011/0184491	A1	7/2011	Kivi
2009/0198295	A1	8/2009	Dennis et al.	2011/0190835	A1	8/2011	Brockway et al.
2009/0198308	A1	8/2009	Gross et al.	2011/0208260	A1	8/2011	Jacobson
2009/0204163	A1	8/2009	Shuros et al.	2011/0218587	A1	9/2011	Jacobson
2009/0204170	A1	8/2009	Hastings et al.	2011/0230734	A1	9/2011	Fain et al.
2009/0210024	A1	8/2009	M.	2011/0237967	A1	9/2011	Moore et al.
2009/0216292	A1	8/2009	Pless et al.	2011/0245782	A1	10/2011	Berthiaume et al.
2009/0234407	A1	9/2009	Hastings et al.	2011/0245890	A1	10/2011	Brisben et al.
2009/0234411	A1	9/2009	Sambelashvili et al.	2011/0251660	A1	10/2011	Griswold
2009/0266573	A1	10/2009	Engmark et al.	2011/0251662	A1	10/2011	Griswold et al.
2009/0275998	A1	11/2009	Burnes et al.	2011/0270099	A1	11/2011	Ruben et al.
2009/0275999	A1	11/2009	Burnes et al.	2011/0270339	A1	11/2011	Murray, III et al.
2009/0299447	A1	12/2009	Jensen et al.	2011/0270340	A1	11/2011	Pellegrini et al.
2009/0326601	A1	12/2009	Brisken et al.	2011/0270341	A1	11/2011	Ruben et al.
2010/0013668	A1	1/2010	Kantervik	2011/0276102	A1	11/2011	Cohen
2010/0016911	A1	1/2010	Willis et al.	2011/0282423	A1	11/2011	Jacobson
2010/0023085	A1	1/2010	Wu et al.	2011/0313490	A1	12/2011	Parramon et al.
2010/0030061	A1	2/2010	Canfield et al.	2012/0004527	A1	1/2012	Thompson et al.
2010/0030327	A1	2/2010	Chatel	2012/0029323	A1	2/2012	Zhao
2010/0042108	A1	2/2010	Hibino	2012/0041508	A1	2/2012	Rouso et al.
2010/0049270	A1	2/2010	Pastore et al.	2012/0059431	A1	3/2012	Williams et al.
2010/0056871	A1	3/2010	Govari et al.	2012/0059433	A1	3/2012	Cowan et al.
2010/0063375	A1	3/2010	Kassab et al.	2012/0059436	A1	3/2012	Fontaine et al.
2010/0063562	A1	3/2010	Cowan et al.	2012/0065500	A1	3/2012	Rogers et al.
2010/0069983	A1	3/2010	Peacock, III et al.	2012/0078322	A1	3/2012	Dal Molin et al.
2010/0094367	A1	4/2010	Sen	2012/0081201	A1	4/2012	Norgaard et al.
2010/0114209	A1	5/2010	Krause et al.	2012/0089198	A1	4/2012	Ostroff
2010/0114214	A1	5/2010	Morelli et al.	2012/0093245	A1	4/2012	Makdissi et al.
2010/0125281	A1	5/2010	Jacobson et al.	2012/0095521	A1	4/2012	Hintz
2010/0161002	A1	6/2010	Aghassian et al.	2012/0095539	A1	4/2012	Khairkhahan et al.
2010/0168761	A1	7/2010	Kassab et al.	2012/0101392	A1	4/2012	Bhunja et al.
2010/0168819	A1	7/2010	Freeberg	2012/0101540	A1	4/2012	O'Brien et al.
2010/0179628	A1	7/2010	Towe et al.	2012/0101553	A1	4/2012	Reddy
2010/0198288	A1	8/2010	Ostroff	2012/0109148	A1	5/2012	Bonner et al.
2010/0198294	A1	8/2010	Kaiser	2012/0109149	A1	5/2012	Bonner et al.
2010/0198304	A1	8/2010	Wang	2012/0109236	A1	5/2012	Jacobson et al.
2010/0217367	A1	8/2010	Belson	2012/0109259	A1	5/2012	Bond et al.
2010/0228308	A1	9/2010	Cowan et al.	2012/0116489	A1	5/2012	Khairkhahan et al.
2010/0234906	A1	9/2010	Koh	2012/0143271	A1	6/2012	Root et al.
2010/0234924	A1	9/2010	Willis	2012/0150251	A1	6/2012	Giftakis et al.
2010/0241185	A1	9/2010	Mahapatra et al.	2012/0158090	A1	6/2012	Chavan et al.
2010/0249729	A1	9/2010	Morris et al.	2012/0158111	A1	6/2012	Khairkhahan et al.
2010/0249883	A1	9/2010	Zdeblick	2012/0165827	A1	6/2012	Khairkhahan et al.
2010/0249885	A1	9/2010	Colvin et al.	2012/0172690	A1	7/2012	Anderson et al.
2010/0286744	A1	11/2010	Echt et al.	2012/0172891	A1	7/2012	Lee
2010/0298841	A1	11/2010	Prinzen et al.	2012/0172892	A1	7/2012	Grubac et al.
2010/0304209	A1	12/2010	Lund et al.	2012/0172942	A1	7/2012	Berg
2010/0305627	A1	12/2010	Anderson	2012/0172943	A1	7/2012	Limousin
2010/0305628	A1	12/2010	Lund et al.	2012/0179219	A1	7/2012	Kisker et al.
2010/0305629	A1	12/2010	Lund et al.	2012/0197350	A1	8/2012	Roberts et al.
2010/0312309	A1	12/2010	Harding	2012/0197352	A1	8/2012	Carbunaru et al.
2010/0312320	A1	12/2010	Faltys et al.	2012/0197373	A1	8/2012	Khairkhahan et al.
2011/0022113	A1	1/2011	Zdeblick et al.	2012/0215274	A1	8/2012	Koh et al.
2011/0054555	A1	3/2011	Williams et al.	2012/0215285	A1	8/2012	Tahmasian et al.
2011/0060392	A1	3/2011	Zdeblick et al.	2012/0232371	A1	9/2012	Meeh et al.
2011/0071585	A1	3/2011	Ransbury et al.	2012/0232565	A1	9/2012	Kveen et al.
2011/0071586	A1	3/2011	Jacobson	2012/0245665	A1	9/2012	Friedman et al.
2011/0077707	A1	3/2011	Maile et al.	2012/0271186	A1	10/2012	Siejko et al.
2011/0077708	A1	3/2011	Ostroff	2012/0277600	A1	11/2012	Greenhut
				2012/0277606	A1	11/2012	Ellingson et al.
				2012/0283795	A1	11/2012	Stancer et al.
				2012/0283807	A1	11/2012	Deterre et al.
				2012/0289776	A1	11/2012	Keast et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2012/0289815	A1	11/2012	Keast et al.	2013/0274828	A1	10/2013	Willis
2012/0290021	A1	11/2012	Saurkar et al.	2013/0274847	A1	10/2013	Ostroff
2012/0290025	A1	11/2012	Keimel	2013/0282070	A1	10/2013	Cowan et al.
2012/0296381	A1	11/2012	Matos	2013/0282073	A1	10/2013	Cowan et al.
2012/0303082	A1	11/2012	Dong et al.	2013/0296727	A1	11/2013	Sullivan et al.
2012/0316613	A1	12/2012	Keefe et al.	2013/0302665	A1	11/2013	Zhao et al.
2012/0316622	A1	12/2012	Whitehurst et al.	2013/0303872	A1	11/2013	Taff et al.
2012/0323099	A1	12/2012	Mothilal et al.	2013/0324825	A1	12/2013	Ostroff et al.
2012/0330174	A1	12/2012	Carlson et al.	2013/0325081	A1	12/2013	Karst et al.
2013/0012151	A1	1/2013	Hankins	2013/0331903	A1	12/2013	Lovett et al.
2013/0023975	A1	1/2013	Locsin	2013/0345770	A1	12/2013	Dianaty et al.
2013/0030483	A1	1/2013	Demmer et al.	2014/0005988	A1	1/2014	Brockway
2013/0035748	A1	2/2013	Bonner et al.	2014/0012342	A1	1/2014	Penner et al.
2013/0041422	A1	2/2013	Jacobson	2014/0012344	A1	1/2014	Hastings et al.
2013/0053716	A1	2/2013	Zhang et al.	2014/0018688	A1	1/2014	Song et al.
2013/0053907	A1	2/2013	Kirchner et al.	2014/0018876	A1	1/2014	Ostroff
2013/0053908	A1	2/2013	Smith et al.	2014/0018877	A1	1/2014	Demmer et al.
2013/0053913	A1	2/2013	Koh et al.	2014/0026016	A1	1/2014	Nicholes
2013/0053915	A1	2/2013	Holmstrom et al.	2014/0031836	A1	1/2014	Ollivier
2013/0053921	A1	2/2013	Bonner et al.	2014/0031837	A1	1/2014	Perryman et al.
2013/0060298	A1	3/2013	Splett et al.	2014/0039570	A1	2/2014	Carroll et al.
2013/0066169	A1	3/2013	Rys et al.	2014/0039578	A1	2/2014	Whitehurst et al.
2013/0072770	A1	3/2013	Rao et al.	2014/0039588	A1	2/2014	Ok et al.
2013/0073004	A1	3/2013	Root et al.	2014/0039591	A1	2/2014	Drasler et al.
2013/0079798	A1	3/2013	Tran et al.	2014/0043146	A1	2/2014	Makdissi et al.
2013/0079861	A1	3/2013	Reinert et al.	2014/0046200	A1	2/2014	Patangay et al.
2013/0085350	A1	4/2013	Schugt et al.	2014/0046395	A1	2/2014	Regnier et al.
2013/0085403	A1	4/2013	Gunderson et al.	2014/0046420	A1	2/2014	Moore et al.
2013/0085407	A1	4/2013	Siejko et al.	2014/0058240	A1	2/2014	Mothilal et al.
2013/0085550	A1	4/2013	Polefko et al.	2014/0058494	A1	2/2014	Ostroff et al.
2013/0096649	A1	4/2013	Martin et al.	2014/0072872	A1	3/2014	Hodgkinson et al.
2013/0103047	A1	4/2013	Steingisser et al.	2014/0074114	A1	3/2014	Khairkahan et al.
2013/0103109	A1	4/2013	Jacobson	2014/0074186	A1	3/2014	Faltys et al.
2013/0110008	A1	5/2013	Bourget et al.	2014/0094891	A1	4/2014	Pare et al.
2013/0110127	A1	5/2013	Bornzin et al.	2014/0100624	A1	4/2014	Ellingson
2013/0110192	A1	5/2013	Tran et al.	2014/0100627	A1	4/2014	Min
2013/0110219	A1	5/2013	Bornzin et al.	2014/0107723	A1	4/2014	Hou et al.
2013/0116529	A1	5/2013	Min et al.	2014/0121719	A1	5/2014	Bonner et al.
2013/0116738	A1	5/2013	Samade et al.	2014/0121720	A1	5/2014	Bonner et al.
2013/0116740	A1	5/2013	Bornzin et al.	2014/0121722	A1	5/2014	Sheldon et al.
2013/0116741	A1	5/2013	Bornzin et al.	2014/0128935	A1	5/2014	Kumar et al.
2013/0123872	A1	5/2013	Bornzin et al.	2014/0135865	A1	5/2014	Hastings et al.
2013/0123875	A1	5/2013	Varady et al.	2014/0142648	A1	5/2014	Smith et al.
2013/0131159	A1	5/2013	Ko et al.	2014/0148675	A1	5/2014	Nordstrom et al.
2013/0131591	A1	5/2013	Berthiaume et al.	2014/0148815	A1	5/2014	Wenzel et al.
2013/0131693	A1	5/2013	Berthiaume et al.	2014/0155950	A1	6/2014	Hastings et al.
2013/0138006	A1	5/2013	Bornzin et al.	2014/0169162	A1	6/2014	Romano et al.
2013/0150695	A1	6/2013	Biela et al.	2014/0172060	A1	6/2014	Bornzin et al.
2013/0150911	A1	6/2013	Perschbacher et al.	2014/0180306	A1	6/2014	Bornzin et al.
2013/0150912	A1	6/2013	Perschbacher et al.	2014/0180366	A1	6/2014	Grubac et al.
2013/0184776	A1	7/2013	Shuros et al.	2014/0207149	A1	6/2014	Edlund
2013/0184790	A1	7/2013	Schleicher et al.	2014/0207210	A1	7/2014	Hastings et al.
2013/0192611	A1	8/2013	Taepke, II et al.	2014/0214104	A1	7/2014	Willis et al.
2013/0196703	A1	8/2013	Masoud et al.	2014/0222015	A1	7/2014	Greenhut et al.
2013/0197609	A1	8/2013	Moore et al.	2014/0222098	A1	8/2014	Keast et al.
2013/0226259	A1	8/2013	Penner et al.	2014/0222109	A1	8/2014	Baru et al.
2013/0231710	A1	9/2013	Jacobson	2014/0228913	A1	8/2014	Moulder
2013/0234692	A1	9/2013	Liang et al.	2014/0236172	A1	8/2014	Molin et al.
2013/0235663	A1	9/2013	Walsh et al.	2014/0243848	A1	8/2014	Hastings et al.
2013/0235672	A1	9/2013	Walsh et al.	2014/0255298	A1	8/2014	Auricchio et al.
2013/0238044	A1	9/2013	Penner	2014/0257324	A1	9/2014	Cole et al.
2013/0238056	A1	9/2013	Poore et al.	2014/0257422	A1	9/2014	Fain
2013/0238072	A1	9/2013	Deterre et al.	2014/0257444	A1	9/2014	Herken
2013/0238073	A1	9/2013	Makdissi et al.	2014/0276929	A1	9/2014	Cole et al.
2013/0238840	A1	9/2013	Walsh et al.	2014/0300704	A1	9/2014	Foster et al.
2013/0253309	A1	9/2013	Allan et al.	2014/0303704	A1	10/2014	Suwito et al.
2013/0253342	A1	9/2013	Griswold et al.	2014/0309706	A1	10/2014	Suwito et al.
2013/0253343	A1	9/2013	Waldhauser et al.	2014/0343348	A1	10/2014	Jacobson
2013/0253344	A1	9/2013	Griswold et al.	2014/0371818	A1	11/2014	Kaplan et al.
2013/0253345	A1	9/2013	Griswold et al.	2014/0379041	A1	12/2014	Bond et al.
2013/0253346	A1	9/2013	Griswold et al.	2015/0025612	A1	12/2014	Foster
2013/0253347	A1	9/2013	Griswold et al.	2015/0039041	A1	1/2015	Haasl et al.
2013/0261497	A1	10/2013	Pertijs et al.	2015/0045868	A1	2/2015	Smith et al.
2013/0265144	A1	10/2013	Banna et al.	2015/0051609	A1	2/2015	Bonner et al.
2013/0268042	A1	10/2013	Hastings et al.	2015/0051610	A1	2/2015	Schmidt et al.
				2015/0051611	A1	2/2015	Schmidt et al.
				2015/0051612	A1	2/2015	Schmidt et al.
				2015/0051613	A1	2/2015	Schmidt et al.
				2015/0051614	A1	2/2015	Schmidt et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2015/0051615 A1 2/2015 Schmidt et al.
 2015/0051616 A1 2/2015 Haasl et al.
 2015/0051682 A1 2/2015 Schmidt et al.
 2015/0057520 A1 2/2015 Foster et al.
 2015/0057558 A1 2/2015 Stahmann et al.
 2015/0057721 A1 2/2015 Stahmann et al.
 2015/0088155 A1 3/2015 Stahmann et al.
 2015/0105836 A1 4/2015 Bonner et al.
 2015/0126854 A1 5/2015 Keast et al.
 2015/0142069 A1 5/2015 Sambelashvili
 2015/0157861 A1 6/2015 Aghassian
 2015/0157866 A1 6/2015 Demmer et al.
 2015/0173655 A1 6/2015 Demmer et al.
 2015/0190638 A1 7/2015 Smith et al.
 2015/0196756 A1 7/2015 Stahmann et al.
 2015/0196757 A1 7/2015 Stahmann et al.
 2015/0196758 A1 7/2015 Stahmann et al.
 2015/0196769 A1 7/2015 Stahmann et al.
 2015/0217119 A1 8/2015 Nikolski et al.
 2015/0221898 A1 8/2015 Chi et al.
 2015/0224315 A1 8/2015 Stahmann
 2015/0224320 A1 8/2015 Stahmann
 2015/0230699 A1 8/2015 Berul et al.
 2015/0238769 A1 8/2015 Demmer et al.
 2015/0258345 A1 9/2015 Smith et al.
 2015/0290468 A1 10/2015 Zhang
 2015/0297905 A1 10/2015 Greenhut et al.
 2015/0297907 A1 10/2015 Zhang
 2015/0305637 A1 10/2015 Greenhut et al.
 2015/0305638 A1 10/2015 Zhang
 2015/0305639 A1 10/2015 Greenhut et al.
 2015/0305640 A1 10/2015 Reinke et al.
 2015/0305641 A1 10/2015 Stadler et al.
 2015/0305642 A1 10/2015 Reinke et al.
 2015/0306374 A1 10/2015 Seifert et al.
 2015/0306375 A1 10/2015 Marshall et al.
 2015/0306401 A1 10/2015 Demmer et al.
 2015/0306406 A1 10/2015 Crutchfield et al.
 2015/0306407 A1 10/2015 Crutchfield et al.
 2015/0306408 A1 10/2015 Greenhut et al.
 2015/0321016 A1 11/2015 O'Brien et al.
 2015/0328459 A1 11/2015 Chin et al.
 2015/0335884 A1 11/2015 Khairkahan et al.
 2015/0342492 A1 12/2015 Thakur et al.
 2016/0015322 A1 1/2016 Anderson et al.
 2016/0023000 A1 1/2016 Cho et al.
 2016/0030757 A1 2/2016 Jacobson
 2016/0033177 A1 2/2016 Barot et al.
 2016/0059024 A1 3/2016 Stahmann et al.
 2016/0121127 A1 5/2016 Klimovitch et al.
 2016/0121128 A1 5/2016 Fishier et al.
 2016/0121129 A1 5/2016 Persson et al.
 2016/0213919 A1 7/2016 Suwito et al.
 2016/0213937 A1 7/2016 Reinke et al.
 2016/0213939 A1 7/2016 Carney et al.
 2016/0228026 A1 8/2016 Jackson
 2016/0317825 A1 11/2016 Jacobson
 2016/0367823 A1 12/2016 Cowan et al.
 2017/0014629 A1 1/2017 Ghosh et al.
 2017/0035315 A1 2/2017 Jackson
 2017/0043173 A1 2/2017 Sharma et al.
 2017/0043174 A1 2/2017 Greenhut et al.
 2017/0189681 A1 7/2017 Anderson
 2017/0281261 A1 10/2017 Shuros et al.
 2017/0281952 A1 10/2017 Shuros et al.
 2017/0281953 A1 10/2017 Min et al.
 2017/0281955 A1 10/2017 Maile et al.
 2017/0312531 A1 11/2017 Sawchuk

FOREIGN PATENT DOCUMENTS

AU 2014203793 A1 7/2014
 CA 1003904 A1 1/1977
 CN 101185789 A 5/2008
 CN 101284160 A 10/2008

CN 202933393 U 5/2013
 EP 0362611 A1 4/1990
 EP 503823 A2 9/1992
 EP 1493460 A1 5/2005
 EP 1541191 A1 6/2005
 EP 1702648 A2 9/2006
 EP 1904166 B1 6/2011
 EP 2471452 A1 7/2012
 EP 2526999 A1 11/2012
 EP 2433675 B1 1/2013
 EP 2441491 B1 1/2013
 EP 2452721 B1 11/2013
 EP 2662113 A3 11/2013
 EP 1948296 B1 1/2014
 EP 2760541 B1 5/2016
 EP 2833966 B1 5/2016
 JP 2000051373 A 2/2000
 JP 2002502640 A 1/2002
 JP 2004512105 A 4/2004
 JP 2005508208 A 3/2005
 JP 2005245215 A 9/2005
 JP 2008540040 A 11/2008
 JP 5199867 B2 2/2013
 TW 1251986 B 3/2006
 TW 1252007 B 3/2006
 WO 9500202 A1 1/1995
 WO 9636134 A1 11/1996
 WO 9724981 A2 7/1997
 WO 9826840 A1 6/1998
 WO 9939767 A1 8/1999
 WO 0234330 A2 5/2002
 WO 02098282 A2 12/2002
 WO 2005000206 A3 1/2005
 WO 2005035048 A2 4/2005
 WO 2005042089 A1 5/2005
 WO 2006065394 A1 6/2006
 WO 2006081434 A1 8/2006
 WO 2006086435 A3 8/2006
 WO 2006099425 A1 9/2006
 WO 2006113659 A1 10/2006
 WO 2006124833 A3 11/2006
 WO 2007073435 A1 6/2007
 WO 2007075974 A2 7/2007
 WO 2007117835 A1 10/2007
 WO 2009006531 A1 1/2009
 WO 2009052480 A2 4/2009
 WO 2012054102 A1 4/2012
 WO 2012057662 A1 5/2012
 WO 2012150000 A2 11/2012
 WO 2012154599 A2 11/2012
 WO 2013080038 A2 6/2013
 WO 2013098644 A3 7/2013
 WO 2013121431 A1 8/2013
 WO 2013184787 A1 12/2013
 WO 2014046662 A1 3/2014
 WO 2014120769 A1 8/2014
 WO 2014123512 A1 8/2014

OTHER PUBLICATIONS

US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn)
 "Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter," Nanostim Leadless Pacemakers, pp. 1-28, 2013.
 Asirvatham et al., "Intramyocardial Pacing and Sensing for the Enhancement of Cardiac Stimulation and Sensing Specificity," PACE, vol. 30, pp. 748-754, Jun. 2007.
 Hachisuka et al., "Development and Performance Analysis of an Intra-Body Communication Device," The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.
 Henz et al., "Synchronous Ventricular Pacing without Crossing the Tricuspid Valve or Entering the Coronary Sinus-Preliminary Results," Journal of Cardiovascular Electrophysiology, vol. 20(12):1391-1397, Dec. 2009.doi: 10.1111/j.1540-8167.2009.01556.x.
 Hyde et al., Beneficial Effect on Cardiac Resynchronization From Left Ventricular Endocardial Pacing Is Mediated by Early Access to

(56)

References Cited

OTHER PUBLICATIONS

High Conduction Velocity Tissue Electrophysiological Simulation Study, *Circ Arrhythm Electrophysiol*, 8, 1164-1172, 2015, DOI: 10.1161/CIRCEP.115.002677.

Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated Jan. 29, 2016, 15 pages.

Rad et al., Left ventricular septum pacing by transvenous approach through the interventricular septum, Maastricht University Medical Center.

Seyedi et al., "A Survey on Intra-body Communications for Body Area Network Application," *IEEE Transactions on Biomedical Engineering*, vol. 60(8): 2067-2079, 2013.

Spickler et al., "Totally Self-Contained Intracardiac Pacemaker," *Journal of Electrocardiology*, vol. 3(384): 324-331, 1970.

Wegmüller, "Intra-Body Communication for Biomedical Sensor Networks," Diss. ETH, No. 17323, 1-173, 2007.

Delnoy, Peter Paul et al., "Validation of a peak endocardial acceleration based algorithm to optimize cardiac resynchronization: early clinical results," *Eurospace*, 10:801-8 (2008).

(PCT/US2015/040863) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Oct. 9, 2015, 11 pages.

International Search Report and Written Opinion dated Sep. 12, 2017 for International Application No. PCT/US2017/040754.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13

1

**METHOD AND SYSTEM FOR
DETERMINING AN ATRIAL CONTRACTION
TIMING FIDUCIAL IN A LEADLESS
CARDIAC PACEMAKER SYSTEM**

CROSS REFERENCE TO RELATED
APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/359,055 filed on Jul. 6, 2016, the disclosure of which is incorporated herein by reference.

TECHNICAL FIELD

The present disclosure generally relates to implantable medical devices, and more particularly, to systems that use a leadless cardiac pacemaker for monitoring, pacing and/or defibrillating a patient's heart.

BACKGROUND

Implantable medical devices are commonly used today to monitor a patient and/or deliver therapy to a patient. For example and in some instances, pacing devices are used to treat patients suffering from various heart conditions that may result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. Such heart conditions may lead to slow, rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various medical devices (e.g., pacemakers, defibrillators, etc.) can be implanted in a patient's body. Such devices may monitor and in some cases provide electrical stimulation (e.g. pacing, defibrillation, etc.) to the heart to help the heart operate in a more normal, efficient and/or safe manner. In some cases, it is beneficial to sense and/or pace two or more chambers of the heart, such as to provide cardiac resynchronization therapy (CRT).

SUMMARY

This disclosure generally relates to implantable medical devices, and more particularly, to systems that use a leadless cardiac pacemaker for monitoring, pacing and/or defibrillating a patient's heart. In an example of the disclosure, a method for generating a ventricle pacing pulse may include sensing for a mechanical response to an atrial contraction of a patient's heart, and sensing for an electrical cardiac signal associated with the atrial contraction of the patient's heart via an electrode arrangement. An atrial contraction timing fiducial may be determined based at least in part on the sensed mechanical response to the atrial contraction and the sensed electrical cardiac signal associated with the atrial contraction. The atrial contraction timing fiducial can be performed on a beat-by-beat basis, may be average over more than one beat, and/or may be determined in any other suitable manner. In some cases, the mechanical response to the atrial contraction of the patient's heart and the electrical cardiac signal associated with the atrial contraction of the patient's heart may be sensed by a Leadless Cardiac Pacemaker (LCP) implanted in a ventricle of the heart (e.g. at the apex of the left ventricle) and/or by a Subcutaneous Implantable Cardioverter Defibrillator (SICD) implanted subcutaneously. A ventricle pacing pulse may be generated after an A-V delay following the atrial contraction timing fiducial. The ventricle pacing pulse may be generated and delivered by an LCP.

2

Alternatively or additionally to any of the embodiments above, the mechanical response to the atrial contraction of the patient's heart may be sensed via an accelerometer of a Leadless Cardiac Pacemaker (LCP) and/or an accelerometer of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

Alternatively or additionally to any of the embodiments above, the electrical cardiac signal associated with the atrial contraction of the patient's heart may be sensed via an electrode arrangement of a Leadless Cardiac Pacemaker (LCP) and/or an electrode arrangement of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

Alternatively or additionally to any of the embodiments above, the method may further include weighting a timing associated with the sensed mechanical response to the atrial contraction with a first weight, weighting a timing associated with the sensed electrical cardiac signal associated with the atrial contraction with a second weight and determining the atrial contraction timing fiducial based at least in part on the weighted timing associated with the sensed mechanical response and the weighted timing associated with the sensed electrical cardiac signal.

Alternatively or additionally to any of the embodiments above, the sensed mechanical response to the atrial contraction of the patient's heart may be used to identify a time window in which an electrical cardiac signal is searched to identify the electrical cardiac signal associated with a subsequent atrial contraction.

Alternatively or additionally to the previous embodiment above, the sensed mechanical response includes the S3 and the S4 heart sounds, the time window is between the S3 to S4 heart sounds, and the electrical cardiac signal associated with the atrial contraction is a P-wave of an electrocardiogram signal.

Alternatively or additionally to any of the embodiments above, the sensed mechanical response to the atrial contraction of the patient's heart may have a signal-to-noise ratio (SNR) and the sensed electrical cardiac signal associated with the atrial contraction may have a signal-to-noise ratio (SNR). If the signal-to-noise ratio (SNR) of the sensed mechanical response to the atrial contraction of the patient's heart is above a SNR threshold, the atrial contraction timing fiducial may be based on the mechanical response to the atrial contraction of the patient's heart and if the signal-to-noise ratio (SNR) of the sensed mechanical response to the atrial contraction of the patient's heart is below the SNR threshold, the atrial contraction timing fiducial may be based on the electrical cardiac signal associated with the atrial contraction of the patient's heart.

Alternatively or additionally to any of the embodiments above, the method may further include detecting an ambulatory activity level of the patient. When so provided, the atrial contraction timing fiducial may be based on the mechanical response to the atrial contraction of the patient's heart if the detected ambulatory activity level is below an activity threshold and may be based on the electrical cardiac signal associated with the atrial contraction of the patient's heart if the detected ambulatory activity level is above the activity threshold.

Alternatively or additionally to any of the embodiments above, the method may further include detecting a posture of the patient. When so provided, the atrial contraction timing fiducial may be based on the mechanical response to the atrial contraction of the patient's heart if the patient is in a first posture and may be based on the electrical cardiac

signal associated with the atrial contraction of the patient's heart if the patient is in a second posture that is different from the first posture.

Alternatively or additionally to any of the embodiments above, the electrode arrangement may be configured to provide two or more sense vectors for sensing electrical cardiac signals associated with the atrial contractions of the patient's heart. When so provided, the method may include sensing for the electrical cardiac signals associated with one or more atrial contractions of the patient's heart using a first sense vector of the two or more sense vectors of the electrode arrangement, and sensing for the electrical cardiac signals associated with one or more atrial contractions of the patient's heart using a second sense vector of the two or more sense vectors of the electrode arrangement. A determination may be made as to which of the first sense vector and the second sense vector produces a higher signal-to-noise ratio (SNR) for the electrical cardiac signals associated with the one or more atrial contractions of the patient's heart. The sense vector determined to produce the higher signal-to-noise ratio (SNR) may be used when sensing electrical cardiac signals associated with subsequent atrial contractions of the patient's heart.

Alternatively or additionally to any of the embodiments above, the electrode arrangement may be configured to provide two or more sense vectors for sensing the electrical cardiac signal associated with the atrial contraction of the patient's heart. When so provided, the method may include sensing for the electrical cardiac signals associated with the atrial contractions of the patient's heart using each of two or more sense vectors of the two or more sense vectors of the electrode arrangement, determining a composite sense vector of the two or more sense vectors that increases the signal-to-noise ratio (SNR) relative to a SNR achievable by any one of the individual sense vectors, and using the composite sense vector when sensing for electrical cardiac signals associated with subsequent atrial contractions of the patient's heart.

In another example of the disclosure, a leadless cardiac pacemaker (LCP) is configured to sense cardiac activity and to pace a patient's heart and is disposable within a ventricle of the patient's heart. The LCP includes a housing, a first electrode secured relative to the housing and exposed to an environment outside of the housing and a second electrode secured relative to the housing and exposed to the environment outside of the housing, the second electrode spaced from the first electrode. A controller is disposed within the housing and is operably coupled to the first electrode and the second electrode such that the controller is capable of receiving, via the first electrode and the second electrode, electrical signals including an electrical indication of atrial contraction. An accelerometer is disposed within the housing and is operably coupled to the controller. The controller is configured to detect, via a signal from the accelerometer, a mechanical indication of atrial contraction. The controller is further configured to determine an atrial contraction timing fiducial based at least in part on the mechanical indication of atrial contraction and/or the electrical indication of atrial contraction, and to generate a ventricle pacing pulse after an A-V delay following the atrial contraction timing fiducial.

Alternatively or additionally to any of the embodiments above, the electrical indication of atrial contraction may include a P-wave of an electrocardiogram.

Alternatively or additionally to any of the embodiments above, the mechanical indication of atrial contraction may include an S4 heart sound.

Alternatively or additionally to any of the embodiments above, the electrical indication of atrial contraction may be received from a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

Alternatively or additionally to any of the embodiments above, the controller may be configured to preferentially use the electrical indication of atrial contraction or the mechanical indication of atrial contraction based at least in part upon a signal-to-noise ratio (SNR) associated with each.

In another example of the disclosure, a system for generating a ventricle pacing pulse may include a Subcutaneous Implantable Cardioverter Defibrillator (SICD), and a leadless cardiac pacemaker (LCP) in operative communication with the SICD. At least one of the SICD and LCP may sense for a mechanical response to an atrial contraction of a patient's heart and at least one of the SICD and LCP may sense for an electrical cardiac signal associated with the atrial contraction of the patient's heart. An atrial contraction timing fiducial is stored in the LCP, wherein the atrial contraction timing fiducial based at least in part on the sensed mechanical response to the atrial contraction and the sensed electrical cardiac signal associated with the atrial contraction. The LCP may generate a ventricle pacing pulse after an A-V delay following the atrial contraction timing fiducial.

Alternatively or additionally to any of the embodiments above, the mechanical response to the atrial contraction of the patient's heart is sensed via an accelerometer of the LCP and/or an accelerometer of the SICD.

Alternatively or additionally to any of the embodiments above, the electrical cardiac signal associated with the atrial contraction of the patient's heart is sensed via an electrode arrangement of the LCP and/or an electrode arrangement of the SICD.

Alternatively or additionally to any of the embodiments above, the sensed mechanical response to the atrial contraction of the patient's heart has a signal-to-noise ratio (SNR) and the sensed electrical cardiac signal associated with the atrial contraction has a signal-to-noise ratio (SNR). If the SNR of the sensed mechanical response to the atrial contraction of the patient's heart is above a SNR threshold, the atrial contraction timing fiducial may be based on the mechanical response to the atrial contraction of the patient's heart, and if the SNR of the sensed mechanical response to the atrial contraction of the patient's heart is below the SNR threshold, the atrial contraction timing fiducial may be based on the electrical cardiac signal associated with the atrial contraction of the patient's heart.

The above summary is not intended to describe each embodiment or every implementation of the present disclosure. Advantages and attainments, together with a more complete understanding of the disclosure, will become apparent and appreciated by referring to the following description and claims taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following description of various illustrative embodiments in connection with the accompanying drawings, in which:

FIG. 1 is a highly schematic diagram of an illustrative system in accordance with an example of the disclosure;

5

FIG. 2 is a graphical representation of an electrocardiogram (ECG) showing a temporal relationship between electrical signals of the heart and mechanical indications of contraction of the heart;

FIG. 3 is a schematic block diagram of an illustrative leadless cardiac pacemaker (LCP) useable in the system of FIG. 1;

FIG. 4 is a schematic block diagram of an illustrative LCP in accordance with an example of the disclosure;

FIG. 5 is a schematic block diagram of another illustrative medical device that may be used in conjunction with the LCP of FIG. 4;

FIG. 6 is a schematic diagram of an exemplary medical system that includes multiple LCPs and/or other devices in communication with one another;

FIG. 7 is a schematic diagram of a system including an LCP and another medical device, in accordance with an example of the disclosure;

FIG. 8 is a flow diagram showing an illustrative method in accordance with an example of the disclosure;

FIG. 9 is a flow diagram showing an illustrative method in accordance with an example of the disclosure;

FIG. 10 is a flow diagram showing an illustrative method in accordance with an example of the disclosure;

FIG. 11 is a flow diagram showing an illustrative method in accordance with an example of the disclosure;

FIG. 12 is a flow diagram showing an illustrative method in accordance with an example of the disclosure; and

FIG. 13 is a flow diagram showing an illustrative method in accordance with an example of the disclosure.

While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular illustrative embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

DESCRIPTION

The following description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The description and the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure.

All numbers are herein assumed to be modified by the term “about”, unless the content clearly dictates otherwise. The recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include the plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is

6

described in connection with an embodiment, it is contemplated that the feature, structure, or characteristic may be applied to other embodiments whether or not explicitly described unless clearly stated to the contrary.

A normal, healthy heart induces contraction by conducting intrinsically generated electrical signals throughout the heart. These intrinsic signals cause the muscle cells or tissue of the heart to contract in a coordinated manner. These contractions forces blood out of and into the heart, providing circulation of the blood throughout the rest of the body. Many patients suffer from cardiac conditions that affect the efficient operation of their hearts. For example, some hearts develop diseased tissue that no longer generate or efficiently conduct intrinsic electrical signals. In some examples, diseased cardiac tissue may conduct electrical signals at differing rates, thereby causing an unsynchronized and inefficient contraction of the heart. In other examples, a heart may generate intrinsic signals at such a low rate that the heart rate becomes dangerously low. In still other examples, a heart may generate electrical signals at an unusually high rate, even resulting in cardiac fibrillation. Implantable medical device are often used to treat such conditions by delivering one or more types of electrical stimulation therapy to the patient’s heart.

FIG. 1 is a schematic diagram showing an illustrative system 10 that may be used to sense and/or pace a heart H. In some cases, the system 10 may also be configured to be able to shock the heart H. The heart H includes a right atrium RA and a right ventricle. The heart H also includes a left atrium LA and a left ventricle LV. In some cases, the illustrative system 10 includes an SICD (subcutaneous implantable cardioverter defibrillator) 12. While not shown in this Figure, in some cases the SICD 12 may include a lead that may be configured to be placed subcutaneously relative to a patient’s sternum and outside of the patient’s heart. The SICD 12 may be configured to sense electrical activity generated by the heart H as well as provide electrical energy to the heart H in order to shock the heart H from an undesired heart rhythm to a desired heart rhythm. In some cases, the system 10 may include an LCP 14 that may be configured to sense and/or pace the heart H. While a single LCP 14 is illustrated, it will be appreciated that two or more LCPs 14 may be implanted in or on the heart H. The LCP 14 may be implanted into any chamber of the heart, such as the right atrium RA, the left atrium LA, the right ventricle RV and the left ventricle LV. When more than one LCP is provided, each LCP may be implanted in a different chamber. In some cases, multiple LCP’s may be implanted within a single chamber of the heart H.

In some cases, the SICD 12 and the LCP 14 may be implanted at the same time. In some instances, depending on the cardiac deficiencies of a particular patient, the SICD 12 may be implanted first, and one or more LCPs 14 may be implanted at a later date if/when the patient’s heart decompensates and it becomes necessary to pace the heart H. In some cases, it is contemplated that one or more LCPs 14 may be implanted first, in order to sense and pace the heart H. When a need for possible defibrillation becomes evident, the SICD 12 may subsequently be implanted. Regardless of implantation order or sequence, it will be appreciated that the SICD 12 and the LCP 14 may communicate with each other using any desired communications protocol, such as conducted communication through the patient’s body.

With reference to FIG. 2, it will be appreciated that the heart H is controlled via electrical signals that pass through the cardiac tissue and that can be detected by implanted devices such as but not limited to the SICD 12 and the LCP

14 of FIG. 1. FIG. 2 includes a portion of an electrocardiogram (ECG) 16 along with a heart sounds trace 18. As can be seen in the ECG 16, a heartbeat includes a P-wave that indicates atrial depolarization. A QRS complex, including a Q-wave, an R-wave and an S-wave, represents ventricular depolarization. A T-wave indicates repolarization of the ventricles. It will be appreciated that the ECG 16 may be detected by implanted devices such as but not limited to the SICD 12 and the LCP 14 of FIG. 1.

A number of heart sounds may also be detectable while the heart H beats. It will be appreciated that the heart sounds may be considered as an example of mechanical indications of the heart beating. Other illustrative mechanical indications may include, for example, endocardial acceleration or movement of a heart wall detected by an accelerometer in the LCP, endocardial acceleration or movement of a heart wall detected by an accelerometer in the SICD, a pressure, pressure change, or pressure change rate in a chamber of the heart H detected by a pressure sensor of the LCP, acoustic signals caused by heart movements detected by an acoustic sensor and/or any other suitable indication of a heart chamber beating.

An electrical signal typically causes a portion of the heart H to contract, and then there is a corresponding mechanical indication. In some cases, there may be a first heart sound that is denoted S1 and that is produced by vibrations generated by closure of the mitral and tricuspid valves during a ventricle contraction, a second heart sound that is denoted S2 and that is produced by closure of the aortic and pulmonary valves, a third heart sound that is denoted S3 and that is an early diastolic sound caused by the rapid entry of blood from the right atrium RA into the right ventricle RV and from the left atrium LA into the left ventricle LV, and a fourth heart sound that is denoted S4 and that is a late diastolic sound corresponding to late ventricular filling during an active atrial contraction.

Because the heart sounds are a result of cardiac muscle contracting or relaxing in response to an electrical signal, it will be appreciated that there is a delay between the electrical signal, indicated by the ECG 16, and the corresponding mechanical indication, indicated by the heart sounds trace 18. For example, the P-wave of the ECG 16 is an electrical signal triggering an atrial contraction. The S4 heart sound is the mechanical signal caused by the atrial contraction. In some cases, it may be possible to use this relationship between the P-wave and the S4 heart sound. For example, if one of these signals may be detected, the relationship can be used as a timing mechanism to help search for the other. For example, if the P-wave can be detected, a window following the P-wave can be defined and searched to find the corresponding S4 heart sound. In some cases, detection of both signals may increase the confidence level in a detected atrial contraction. In some cases, detection of either signal may be sufficient to identify an atrial contraction. The identity of an atrial contraction may be used to identify an atrial contraction timing fiducial.

In some cases, the relationship of certain electrical signals and/or mechanical indications may be used to predict the timing of other electrical signals and/or mechanical indications within the same heartbeat. Alternatively, or in addition, the timing of certain electrical signals and/or mechanical indications corresponding to a particular heartbeat may be used to predict the timing of other electrical signals and/or mechanical indications within a subsequent heartbeat.

Returning back to FIG. 1, in some cases at least one of the SICD 12 and the LCP 14 may sense for a mechanical response to an atrial contraction of the heart H. In some

cases, the SICD 12 and the LCP 14 may both sense for a mechanical response. In some cases, only one of the SICD 12 and the LCP 14 may sense for a mechanical response. In some cases, at least one of the SICD 12 and the LCP 14 may sense for an electrical cardiac signal that is associated with atrial contraction. In some cases, both the SICD 12 and the LCP 14 may sense for an electrical cardiac signal while in other cases only one of the SICD 12 and the LCP 14 may do so.

In some cases, an atrial contraction timing fiducial may be stored in the LCP 14. The atrial contraction timing fiducial may be based at least in part on the sensed mechanical response to the atrial contraction and the sensed electrical cardiac signal associated with the atrial contraction. In some cases, the LCP 14 may generate a ventricle pacing pulse after an A-V delay following the atrial contraction timing fiducial. In one example, detecting at least one of the P-wave, indicating the electrical signal instructing the atria to contract, and the S4 heart sound, which is caused by atrial contraction, may be used to determine an atrial contraction timing fiducial and thus when to pace the right ventricle RV and/or the left ventricle LV.

In some cases, the mechanical response to the atrial contraction of the patient's heart H may be sensed via an accelerometer of the LCP 14 and/or an accelerometer of the SICD 12. In some cases, the SICD 12 may include an accelerometer within a lead of the SICD 12. In some instances, the SICD 12 may include an accelerometer with the main housing of the SICD 12. In some cases, the LCP 14 and the SICD 12 may include accelerometers. In some instances, the electrical cardiac signal associated with the atrial contraction of the patient's heart H may be sensed via an electrode arrangement of the LCP 14 and/or an electrode arrangement of the SICD 12. Additional details regarding the SICD 12 and the LCP 14 may be discussed with respect to subsequent Figures. In some instances, the sensed mechanical response to the atrial contractions of the patient's heart may have a signal-to-noise ratio (SNR) and the sensed electrical cardiac signals associated with the atrial contractions have a signal-to-noise ratio (SNR). For example, the noise used for SNR calculating may be the electrical (for electrical SNR) or mechanical (for mechanical SNR) response during a portion of the cardiac cycle not associated with any cardiac activity (such as but not limited to the temporal window between S1 and S2). In some cases, if the SNR of the sensed mechanical response to the atrial contractions of the patient's heart is above a SNR threshold, the atrial contraction timing fiducial is based on the mechanical response to the atrial contractions of the patient's heart. In some instances, if the SNR of the sensed mechanical response to the atrial contractions of the patient's heart is below the SNR threshold, the atrial contraction timing fiducial is based on the electrical cardiac signal associated with the atrial contractions of the patient's heart.

FIG. 3 is a schematic diagram of an illustrative LCP 14. In some cases, as indicated, the LCP 14 may be considered as being configured to sense cardiac activity and to pace a patient's heart H. In some cases, the LCP 14 may be disposable within a ventricle of the heart H, such as the right ventricle RV or the left ventricle LV. The LCP 14 may be considered as including a housing 20, a first electrode 22 that is secured relative to the housing 20 and exposed to an environment outside the housing 20 (e.g. blood, tissue, etc.), and a second electrode 24 that is secured relative to the housing 20 and exposed to the environment outside of the housing 20 (e.g. blood, tissue, etc.). The second electrode 24

may be spaced from the first electrode **22**. In some cases, as illustrated, the first electrode **22** may be disposed at or near a first end **26** of the housing **20** and the second electrode **24** may be disposed at or near a second end **28** of the housing **20**, although this is not required in all cases.

The LCP **14** may further include a controller **30** that is disposed within the housing **20** and that is operably coupled to the first electrode **22** via a first electrical connection **32** and the second electrode **24** via a second electrical connection **34**. In some cases, the controller **30** may be capable of receiving, via the first electrode **22** and the second electrode **24**, electrical signals that include an electrical indication of an atrial (or other) contraction (e.g. a P-wave of an ECG **16**, see FIG. **2**). In some cases, the controller **30** may receive the electrical signals that include an electrical indication of atrial (or other) contractions from a remote device such as the SICD **12** (FIG. **1**).

In some cases, the LCP **14** may include an accelerometer **36** that is disposed within the housing **20** and that is operably coupled to the controller **30** via electrical connections **38**. In some cases, the controller **30** may be configured to detect, via a signal from the accelerometer **36**, a mechanical indication of atrial (or other) contraction. In some cases, the mechanical indication of atrial contraction may include but is not limited to an S4 heart sound. While the LCP **14** is shown as including an accelerometer, it will be appreciated that other sensors may also be able to provide a signal representing a mechanical indication of atrial (or other) contraction. For example, in some cases the LCP **14** may include a microphone. In some cases, the LCP **14** may include a sonomicrometer, a cardiomechanical sensor that includes, for example, embedded piezoelectric material, or other piezoelectric sensors. These are just examples.

In some cases, the controller **30** may be configured to determine an atrial contraction timing fiducial based at least in part on the mechanical indication of atrial contraction and/or the electrical indication of atrial contraction. In some instances, the controller **30** may be configured to preferentially use the electrical indication of atrial contraction or the mechanical indication of atrial contraction based at least in part upon a signal-to-noise ratio (SNR) associated with each signal. In some instances, the controller **30** may be configured to generate a ventricle pacing pulse after an A-V delay following the atrial contraction timing fiducial.

FIG. **4** depicts another illustrative leadless cardiac pacemaker (LCP) that may be implanted into a patient and may operate to deliver appropriate therapy to the heart, such as to deliver anti-tachycardia pacing (ATP) therapy, cardiac resynchronization therapy (CRT), bradycardia therapy, and/or the like. As can be seen in FIG. **4**, the LCP **100** may be a compact device with all components housed within the or directly on a housing **120**. In some cases, the LCP **100** may be considered as being an example of the LCP **14** (FIGS. **1** and **3**). In the example shown in FIG. **4**, the LCP **100** may include a communication module **102**, a pulse generator module **104**, an electrical sensing module **106**, a mechanical sensing module **108**, a processing module **110**, a battery **112**, and an electrode arrangement **114**. The LCP **100** may include more or less modules, depending on the application.

The communication module **102** may be configured to communicate with devices such as sensors, other medical devices such as an SICD, and/or the like, that are located externally to the LCP **100**. Such devices may be located either external or internal to the patient's body. Irrespective of the location, external devices (i.e. external to the LCP **100** but not necessarily external to the patient's body) can communicate with the LCP **100** via communication module

102 to accomplish one or more desired functions. For example, the LCP **100** may communicate information, such as sensed electrical signals, data, instructions, messages, R-wave detection markers, etc., to an external medical device through the communication module **102**. The external medical device may use the communicated signals, data, instructions, messages, R-wave detection markers, etc., to perform various functions, such as determining occurrences of arrhythmias, delivering electrical stimulation therapy, storing received data, and/or performing any other suitable function. The LCP **100** may additionally receive information such as signals, data, instructions and/or messages from the external medical device through the communication module **102**, and the LCP **100** may use the received signals, data, instructions and/or messages to perform various functions, such as determining occurrences of arrhythmias, delivering electrical stimulation therapy, storing received data, and/or performing any other suitable function. The communication module **102** may be configured to use one or more methods for communicating with external devices. For example, the communication module **102** may communicate via radiofrequency (RF) signals, inductive coupling, optical signals, acoustic signals, conducted communication signals, and/or any other signals suitable for communication.

In the example shown in FIG. **4**, the pulse generator module **104** may be electrically connected to the electrodes **114**. In some examples, the LCP **100** may additionally include electrodes **114'**. In such examples, the pulse generator **104** may also be electrically connected to the electrodes **114'**. The pulse generator module **104** may be configured to generate electrical stimulation signals. For example, the pulse generator module **104** may generate electrical stimulation signals by using energy stored in the battery **112** within the LCP **100** and deliver the generated electrical stimulation signals via the electrodes **114** and/or **114'**. Alternatively, or additionally, the pulse generator **104** may include one or more capacitors, and the pulse generator **104** may charge the one or more capacitors by drawing energy from the battery **112**. The pulse generator **104** may then use the energy of the one or more capacitors to deliver the generated electrical stimulation signals via the electrodes **114** and/or **114'**. In at least some examples, the pulse generator **104** of the LCP **100** may include switching circuitry to selectively connect one or more of the electrodes **114** and/or **114'** to the pulse generator **104** in order to select which of the electrodes **114/114'** (and/or other electrodes) the pulse generator **104** delivers the electrical stimulation therapy. The pulse generator module **104** may generate electrical stimulation signals with particular features or in particular sequences in order to provide one or multiple of a number of different stimulation therapies. For example, the pulse generator module **104** may be configured to generate electrical stimulation signals to provide electrical stimulation therapy to combat bradycardia, tachycardia, cardiac synchronization, bradycardia arrhythmias, tachycardia arrhythmias, fibrillation arrhythmias, cardiac synchronization arrhythmias and/or to produce any other suitable electrical stimulation therapy. Some more common electrical stimulation therapies include anti-tachycardia pacing (ATP) therapy, cardiac resynchronization therapy (CRT), and cardioversion/defibrillation therapy.

In some examples, the LCP **100** may not include a pulse generator **104**. For example, the LCP **100** may be a diagnostic only device. In such examples, the LCP **100** may not deliver electrical stimulation therapy to a patient. Rather, the LCP **100** may collect data about cardiac electrical activity and/or physiological parameters of the patient and commu-

nicate such data and/or determinations to one or more other medical devices via the communication module 102.

In some examples, the LCP 100 may include an electrical sensing module 106, and in some cases, a mechanical sensing module 108. The electrical sensing module 106 may be configured to sense the cardiac electrical activity of the heart. For example, the electrical sensing module 106 may be connected to the electrodes 114/114', and the electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through the electrodes 114/114'. The cardiac electrical signals may represent local information from the chamber in which the LCP 100 is implanted. For instance, if the LCP 100 is implanted within a ventricle of the heart, cardiac electrical signals sensed by the LCP 100 through the electrodes 114/114' may represent ventricular cardiac electrical signals. In some cases, the LCP 100 may be configured to detect cardiac electrical signals from other chambers (e.g. far field), such as the P-wave from the atrium.

The mechanical sensing module 108 may include one or more sensors, such as an accelerometer, a pressure sensor, a heart sound sensor, a blood-oxygen sensor, a temperature sensor, a flow sensor and/or any other suitable sensors that are configured to measure one or more mechanical/chemical parameters of the patient. Both the electrical sensing module 106 and the mechanical sensing module 108 may be connected to a processing module 110, which may provide signals representative of the sensed mechanical parameters. Although described with respect to FIG. 4 as separate sensing modules, in some cases, the electrical sensing module 206 and the mechanical sensing module 208 may be combined into a single sensing module, as desired.

The electrodes 114/114' can be secured relative to the housing 120 but exposed to the tissue and/or blood surrounding the LCP 100. In some cases, the electrodes 114 may be generally disposed on either end of the LCP 100 and may be in electrical communication with one or more of the modules 102, 104, 106, 108, and 110. The electrodes 114/114' may be supported by the housing 120, although in some examples, the electrodes 114/114' may be connected to the housing 120 through short connecting wires such that the electrodes 114/114' are not directly secured relative to the housing 120. In examples where the LCP 100 includes one or more electrodes 114', the electrodes 114' may in some cases be disposed on the sides of the LCP 100, which may increase the number of electrodes by which the LCP 100 may sense cardiac electrical activity, deliver electrical stimulation and/or communicate with an external medical device. The electrodes 114/114' can be made up of one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, the electrodes 114/114' connected to the LCP 100 may have an insulative portion that electrically isolates the electrodes 114/114' from adjacent electrodes, the housing 120, and/or other parts of the LCP 100. In some cases, one or more of the electrodes 114/114' may be provided on a tail (not shown) that extends away from the housing 120.

The processing module 110 can be configured to control the operation of the LCP 100. For example, the processing module 110 may be configured to receive electrical signals from the electrical sensing module 106 and/or the mechanical sensing module 108. Based on the received signals, the processing module 110 may determine, for example, abnormalities in the operation of the heart H. Based on any determined abnormalities, the processing module 110 may control the pulse generator module 104 to generate electrical stimulation in accordance with one or more therapies to treat

the determined abnormalities. The processing module 110 may further receive information from the communication module 102. In some examples, the processing module 110 may use such received information to help determine whether an abnormality is occurring, determine a type of abnormality, and/or to take particular action in response to the information. The processing module 110 may additionally control the communication module 102 to send/receive information to/from other devices.

In some examples, the processing module 110 may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip and/or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of the LCP 100. By using a pre-programmed chip, the processing module 110 may use less power than other programmable circuits (e.g. general purpose programmable microprocessors) while still being able to maintain basic functionality, thereby potentially increasing the battery life of the LCP 100. In other examples, the processing module 110 may include a programmable microprocessor. Such a programmable microprocessor may allow a user to modify the control logic of the LCP 100 even after implantation, thereby allowing for greater flexibility of the LCP 100 than when using a pre-programmed ASIC. In some examples, the processing module 110 may further include a memory, and the processing module 110 may store information on and read information from the memory. In other examples, the LCP 100 may include a separate memory (not shown) that is in communication with the processing module 110, such that the processing module 110 may read and write information to and from the separate memory.

The battery 112 may provide power to the LCP 100 for its operations. In some examples, the battery 112 may be a non-rechargeable lithium-based battery. In other examples, a non-rechargeable battery may be made from other suitable materials, as desired. Because the LCP 100 is an implantable device, access to the LCP 100 may be limited after implantation. Accordingly, it is desirable to have sufficient battery capacity to deliver therapy over a period of treatment such as days, weeks, months, years or even decades. In some instances, the battery 112 may be a rechargeable battery, which may help increase the useable lifespan of the LCP 100. In still other examples, the battery 110 may be some other type of power source, as desired.

To implant the LCP 100 inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix the LCP 100 to the cardiac tissue of the patient's heart. To facilitate fixation, the LCP 100 may include one or more anchors 116. The anchor 116 may include any one of a number of fixation or anchoring mechanisms. For example, the anchor 116 may include one or more pins, staples, threads, screws, helix, tines, and/or the like. In some examples, although not shown, the anchor 116 may include threads on its external surface that may run along at least a partial length of the anchor 116. The threads may provide friction between the cardiac tissue and the anchor to help fix the anchor 116 within the cardiac tissue. In other examples, the anchor 116 may include other structures such as barbs, spikes, or the like to facilitate engagement with the surrounding cardiac tissue.

FIG. 5 depicts an example of another medical device (MD) 200, which may be used in conjunction with the LCP 100 (FIG. 4) in order to detect and/or treat cardiac abnormalities. In some cases, the MD 200 may be considered as an example of the SICKD 12 (FIG. 1). In the example shown, the MD 200 may include a communication module 202, a pulse generator module 204, an electrical sensing module

206, a mechanical sensing module 208, a processing module 210, and a battery 218. Each of these modules may be similar to the modules 102, 104, 106, 108, and 110 of LCP 100. Additionally, the battery 218 may be similar to the battery 112 of the LCP 100. In some examples, however, the MD 200 may have a larger volume within the housing 220. In such examples, the MD 200 may include a larger battery and/or a larger processing module 210 capable of handling more complex operations than the processing module 110 of the LCP 100.

While it is contemplated that the MD 200 may be another leadless device such as shown in FIG. 4, in some instances the MD 200 may include leads such as leads 212. The leads 212 may include electrical wires that conduct electrical signals between the electrodes 214 and one or more modules located within the housing 220. In some cases, the leads 212 may be connected to and extend away from the housing 220 of the MD 200. In some examples, the leads 212 are implanted on, within, or adjacent to a heart of a patient. The leads 212 may contain one or more electrodes 214 positioned at various locations on the leads 212, and in some cases at various distances from the housing 220. Some leads 212 may only include a single electrode 214, while other leads 212 may include multiple electrodes 214. Generally, the electrodes 214 are positioned on the leads 212 such that when the leads 212 are implanted within the patient, one or more of the electrodes 214 are positioned to perform a desired function. In some cases, the one or more of the electrodes 214 may be in contact with the patient's cardiac tissue. In some cases, the one or more of the electrodes 214 may be positioned subcutaneously and outside of the patient's heart. In some cases, the electrodes 214 may conduct intrinsically generated electrical signals to the leads 212, e.g. signals representative of intrinsic cardiac electrical activity. The leads 212 may, in turn, conduct the received electrical signals to one or more of the modules 202, 204, 206, and 208 of the MD 200. In some cases, the MD 200 may generate electrical stimulation signals, and the leads 212 may conduct the generated electrical stimulation signals to the electrodes 214. The electrodes 214 may then conduct the electrical signals and delivery the signals to the patient's heart (either directly or indirectly).

The mechanical sensing module 208, as with the mechanical sensing module 108, may contain or be electrically connected to one or more sensors, such as accelerometers, acoustic sensors, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which are configured to measure one or more mechanical/chemical parameters of the heart and/or patient. In some examples, one or more of the sensors may be located on the leads 212, but this is not required. In some examples, one or more of the sensors may be located in the housing 220.

While not required, in some examples, the MD 200 may be an implantable medical device. In such examples, the housing 220 of the MD 200 may be implanted in, for example, a transthoracic region of the patient. The housing 220 may generally include any of a number of known materials that are safe for implantation in a human body and may, when implanted, hermetically seal the various components of the MD 200 from fluids and tissues of the patient's body.

In some cases, the MD 200 may be an implantable cardiac pacemaker (ICP). In this example, the MD 200 may have one or more leads, for example the leads 212, which are implanted on or within the patient's heart. The one or more leads 212 may include one or more electrodes 214 that are in contact with cardiac tissue and/or blood of the patient's

heart. The MD 200 may be configured to sense intrinsically generated cardiac electrical signals and determine, for example, one or more cardiac arrhythmias based on analysis of the sensed signals. The MD 200 may be configured to deliver CRT, ATP therapy, bradycardia therapy, and/or other therapy types via the leads 212 implanted within the heart. In some examples, the MD 200 may additionally be configured provide defibrillation therapy.

In some instances, the MD 200 may be an implantable cardioverter-defibrillator (ICD). In such examples, the MD 200 may include one or more leads implanted within a patient's heart. The MD 200 may also be configured to sense cardiac electrical signals, determine occurrences of tachyarrhythmias based on the sensed signals, and may be configured to deliver defibrillation therapy in response to determining an occurrence of a tachyarrhythmia. In other examples, the MD 200 may be a subcutaneous implantable cardioverter-defibrillator (S-ICD). In examples where the MD 200 is an S-ICD, one of the leads 212 may be a subcutaneously implanted lead. In at least some examples where the MD 200 is an S-ICD, the MD 200 may include only a single lead which is implanted subcutaneously, but this is not required. In some instances, the lead(s) may have one or more electrodes that are placed subcutaneously and outside of the chest cavity. In other examples, the lead(s) may have one or more electrodes that are placed inside of the chest cavity, such as just interior of the sternum.

In some examples, the MD 200 may not be an implantable medical device. Rather, the MD 200 may be a device external to the patient's body, and may include skin-electrodes that are placed on a patient's body. In such examples, the MD 200 may be able to sense surface electrical signals (e.g. cardiac electrical signals that are generated by the heart or electrical signals generated by a device implanted within a patient's body and conducted through the body to the skin). In such examples, the MD 200 may be configured to deliver various types of electrical stimulation therapy, including, for example, defibrillation therapy.

FIG. 6 illustrates an example of a medical device system and a communication pathway through which multiple medical devices 302, 304, 306, and/or 310 may communicate. In the example shown, the medical device system 300 may include LCPs 302 and 304, external medical device 306, and other sensors/devices 310. The external device 306 may be any of the devices described previously with respect to the MD 200. Other sensors/devices 310 may also be any of the devices described previously with respect to the MD 200. In some instances, other sensors/devices 310 may include a sensor, such as an accelerometer, an acoustic sensor, a blood pressure sensor, or the like. In some cases, other sensors/devices 310 may include an external programmer device that may be used to program one or more devices of the system 300.

Various devices of the system 300 may communicate via communication pathway 308. For example, the LCPs 302 and/or 304 may sense intrinsic cardiac electrical signals and may communicate such signals to one or more other devices 302/304, 306, and 310 of the system 300 via communication pathway 308. In one example, one or more of the devices 302/304 may receive such signals and, based on the received signals, determine an occurrence of an arrhythmia. In some cases, the device or devices 302/304 may communicate such determinations to one or more other devices 306 and 310 of the system 300. In some cases, one or more of the devices 302/304, 306, and 310 of the system 300 may take action based on the communicated determination of an arrhythmia, such as by delivering a suitable electrical stimulation to the

heart of the patient. It is contemplated that the communication pathway **308** may communicate using RF signals, inductive coupling, optical signals, acoustic signals, or any other signals suitable for communication. Additionally, in at least some examples, device communication pathway **308** may comprise multiple signal types. For instance, other sensors/device **310** may communicate with the external device **306** using a first signal type (e.g. RF communication) but communicate with the LCPs **302/304** using a second signal type (e.g. conducted communication). Further, in some examples, communication between devices may be limited. For instance, as described above, in some examples, the LCPs **302/304** may communicate with the external device **306** only through other sensors/devices **310**, where the LCPs **302/304** send signals to other sensors/devices **310**, and other sensors/devices **310** relay the received signals to the external device **306**.

In some cases, the communication pathway **308** may include conducted communication. Accordingly, devices of the system **300** may have components that allow for such conducted communication. For instance, the devices of system **300** may be configured to transmit conducted communication signals (e.g. current and/or voltage pulses) into the patient's body via one or more electrodes of a transmitting device, and may receive the conducted communication signals (e.g. pulses) via one or more electrodes of a receiving device. The patient's body may "conduct" the conducted communication signals (e.g. pulses) from the one or more electrodes of the transmitting device to the electrodes of the receiving device in the system **300**. In such examples, the delivered conducted communication signals (e.g. pulses) may differ from pacing or other therapy signals. For example, the devices of the system **300** may deliver electrical communication pulses at an amplitude/pulse width that is sub-threshold to the heart. Although, in some cases, the amplitude/pulse width of the delivered electrical communication pulses may be above the capture threshold of the heart, but may be delivered during a blanking period of the heart and/or may be incorporated in or modulated onto a pacing pulse, if desired.

Delivered electrical communication pulses may be modulated in any suitable manner to encode communicated information. In some cases, the communication pulses may be pulse width modulated or amplitude modulated. Alternatively, or in addition, the time between pulses may be modulated to encode desired information. In some cases, conducted communication pulses may be voltage pulses, current pulses, biphasic voltage pulses, biphasic current pulses, or any other suitable electrical pulse as desired.

FIG. 7 shows an illustrative medical device systems. In FIG. 7, an LCP **402** is shown fixed to the interior of the left ventricle of the heart **410**, and a pulse generator **406** is shown coupled to a lead **412** having one or more electrodes **408a-408c**. In some cases, the pulse generator **406** may be part of a subcutaneous implantable cardioverter-defibrillator (S-ICD), and the one or more electrodes **408a-408c** may be positioned subcutaneously. In some cases, the one or more electrodes **408a-408c** may be placed inside of the chest cavity but outside of the heart, such as just interior of the sternum.

In some cases, the LCP **402** may communicate with the subcutaneous implantable cardioverter-defibrillator (S-ICD). In some cases, the lead **412** may include an accelerometer **414** that may, for example, be configured to sense vibrations that may be indicative of heart sounds.

In some cases, the LCP **302** may be in the right ventricle, right atrium, left ventricle or left atrium of the heart, as

desired. In some cases, more than one LCP **302** may be implanted. For example, one LCP may be implanted in the right ventricle and another may be implanted in the right atrium. In another example, one LCP may be implanted in the right ventricle and another may be implanted in the left ventricle. In yet another example, one LCP may be implanted in each of the chambers of the heart.

When an LCP is placed in, for example, the left ventricle, and no LCP is placed in the left atrium, techniques of the present disclosure may be used to help determine an atrial contraction timing fiducial for the left atrium. This atrial contraction timing fiducial may then be used to determine a proper time to pace the left ventricle via the LCP, such as an AV delay after the atrial contraction timing fiducial.

FIG. 8 is a flow diagram showing an illustrative method for generating a ventricle pacing pulse. As generally shown at block **502**, the method begins with sensing for a mechanical response to an atrial contraction of a patient's heart. In some cases, the mechanical response to the atrial contraction of the patient's heart may be sensed via an accelerometer of a Leadless Cardiac Pacemaker (LCP) and/or an accelerometer of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD). In one particular example, the mechanical response may be sensed by the accelerometer **36** (FIG. 3) of the LCP **14**, **100**, or by the accelerometer **414** of the lead **412** (FIG. 7).

As shown at block **504**, the illustrative method includes sensing for an electrical cardiac signal associated with the atrial contraction of the patient's heart via an electrode arrangement. In some cases, the electrical cardiac signal associated with the atrial contraction of the patient's heart may be sensed via an electrode arrangement of a Leadless Cardiac Pacemaker (LCP) and/or an electrode arrangement of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD). In one particular example, the electrical cardiac signal may be sensed by the first and second electrodes **22**, **24** (LCP **14**) and/or by the electrodes **114**, **114'** (LCP **100**), or perhaps by one or more of the electrodes **408a**, **408b**, **408c** of the lead **412**.

In some cases, a sensed mechanical response to the atrial contraction of the patient's heart may be used to identify a time window in which an electrical cardiac signal is searched to identify the electrical cardiac signal associated with a subsequent atrial contraction. As an illustrative but non-limiting example, a sensed mechanical response may include the S3 and the S4 heart sounds (illustrated in the heart sounds trace **18** of FIG. 2). A time window may be defined between the S3 to S4 heart sounds. A search for the P-wave may be confined to this time window. Likewise, a sensed electrical response to an atrial contraction of the patient's heart may be used to identify a time window in which to search for a corresponding mechanical response. As an illustrative but non-limiting example, after a P-wave is sensed, a window may be defined for a period of time following the P-wave. A search for the S4 heart sound may be confined to this time window. These are just some examples.

An atrial contraction timing fiducial may be determined based at least in part on the sensed mechanical response to the atrial contraction and the sensed electrical cardiac signal associated with the atrial contraction, as seen at block **506**. In some cases, the sensed mechanical response to the atrial contraction of the patient's heart has a signal-to-noise ratio (SNR) and the sensed electrical cardiac signal associated with the atrial contraction has a signal-to-noise ratio (SNR). In some cases, if the signal-to-noise ratio (SNR) of the sensed mechanical response to the atrial contraction of the

patient's heart is above a SNR threshold, the atrial contraction timing fiducial may be based on the mechanical response to the atrial contraction of the patient's heart. Conversely, if the signal-to-noise ratio (SNR) of the sensed mechanical response to the atrial contraction of the patient's heart is below the SNR threshold, the atrial contraction timing fiducial is based on the electrical cardiac signal associated with the atrial contraction of the patient's heart. A ventricle pacing pulse may be generated after an A-V delay following the atrial contraction timing fiducial, as generally indicated at block **508**.

FIG. **9** is a flow diagram showing another illustrative method for generating a ventricle pacing pulse. As generally shown at block **502**, the method begins with sensing for a mechanical response to an atrial contraction of a patient's heart. In some cases, the mechanical response to the atrial contraction of the patient's heart may be sensed via an accelerometer of a Leadless Cardiac Pacemaker (LCP) and/or an accelerometer of a lead of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD). As shown at block **504**, the method further includes sensing for an electrical cardiac signal associated with the atrial contraction of the patient's heart via an electrode arrangement. In some cases, the electrical cardiac signal associated with the atrial contraction of the patient's heart may be sensed via an electrode arrangement of a Leadless Cardiac Pacemaker (LCP) and/or an electrode arrangement of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

As seen at block **510**, in some cases, a timing associated with the sensed mechanical response to the atrial contraction may be weighted with a first weight. In some cases, as seen at block **512**, a timing associated with the sensed electrical cardiac signal associated with the atrial contraction may be weighted with a second weight. The atrial contraction timing fiducial may be determined based at least in part on the weighted timing associated with the sensed mechanical response and the weighted timing associated with the sensed electrical cardiac signal, as generally indicated at block **514**. The first and second weights may be based on a confidence level in the corresponding signals. In some cases, the weights may be based at least in part on the Signal-To-Noise ratio (SNR) of the corresponding signals. A ventricle pacing pulse may be generated after an A-V delay following the atrial contraction timing fiducial, as generally indicated at block **508**.

FIG. **10** is a flow diagram showing another illustrative method for generating a ventricle pacing pulse. As generally shown at block **502**, the method begins with sensing for a mechanical response to an atrial contraction of a patient's heart. In some cases, the mechanical response to the atrial contraction of the patient's heart may be sensed via an accelerometer of a Leadless Cardiac Pacemaker (LCP) and/or an accelerometer of a lead of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD). As shown at block **504**, the method further includes sensing for an electrical cardiac signal associated with the atrial contraction of the patient's heart via an electrode arrangement. In some cases, the electrical cardiac signal associated with the atrial contraction of the patient's heart may be sensed via an electrode arrangement of a Leadless Cardiac Pacemaker (LCP) and/or an electrode arrangement of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

In some cases, an ambulatory activity level of the patient may be detected, as indicated at block **516**. It will be appreciated that the patient's activity level may influence the confidence level in the detected electrical signals of cardiac activity and/or resultant mechanical indications of cardiac

activity. At decision block **518**, a determination may be made if the detected ambulatory activity level is below an activity threshold. The activity threshold may be customized for a particular patient. If the detected ambulatory activity level is below the activity threshold, control passes to block **520** and the atrial contraction timing fiducial may be based on the mechanical response to the atrial contraction of the patient's heart (or may be weighted more heavily). However, if at decision block **518** the detected ambulatory activity level is not below the activity level, control passes to block **522** and the atrial contraction timing fiducial may be based on the electrical cardiac signal associated with the atrial contraction of the patient's heart (or may be weighted more heavily). A ventricle pacing pulse may be generated after an A-V delay following the atrial contraction timing fiducial, as generally indicated at block **508**.

FIG. **11** is a flow diagram showing another illustrative method for generating a ventricle pacing pulse. As generally shown at block **502**, the method begins with sensing for a mechanical response to an atrial contraction of a patient's heart. In some cases, the mechanical response to the atrial contraction of the patient's heart may be sensed via an accelerometer of a Leadless Cardiac Pacemaker (LCP) and/or an accelerometer of a lead of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD). As shown at block **504**, the method further includes sensing for an electrical cardiac signal associated with the atrial contraction of the patient's heart via an electrode arrangement. In some cases, the electrical cardiac signal associated with the atrial contraction of the patient's heart may be sensed via an electrode arrangement of a Leadless Cardiac Pacemaker (LCP) and/or an electrode arrangement of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

In some cases, a posture of the patient may be detected, as indicated at block **516**. It will be appreciated that the patient's posture, whether standing, sitting, laying down, etc., may influence the confidence level in the detected electrical signals of cardiac activity and/or resultant mechanical indications of cardiac activity. At decision block **526**, a determination may be made as to whether the patient is in a first posture or a second posture. If the patient is in a first posture, control passes to block **528** and the atrial contraction timing fiducial may be based on the mechanical response to the atrial contraction of the patient's heart (or may be weighted more heavily). However, if at decision block **526** the patient is in the second posture, control passes to block **530** and the atrial contraction timing fiducial may be based on the electrical cardiac signal associated with the atrial contraction of the patient's heart (or may be weighted more heavily). A ventricle pacing pulse may be generated after an A-V delay following the atrial contraction timing fiducial, as generally indicated at block **508**.

FIG. **12** is a flow diagram showing another illustrative method for generating a ventricle pacing pulse. In some cases, the electrode arrangement used for sensing for an electrical cardiac signal associated with the atrial contraction may be configured to provide two or more sense vectors for sensing the electrical cardiac signal associated with the atrial contraction of the patient's heart. As generally shown at block **540**, the method begins with sensing for the electrical cardiac signals associated with one or more atrial contractions of the patient's heart using a first sense vector of the two or more sense vectors of the electrode arrangement. As shown at block **542**, the method includes sensing for the electrical cardiac signals associated with one or more atrial contractions of the patient's heart using a second sense vector of the two or more sense vectors of the electrode

arrangement. A determination may be made as to which of the first sense vector and the second sense vector produces the higher confidence level (e.g. signal-to-noise ratio (SNR)) for the electrical cardiac signal associated with the one or more atrial contractions of the patient's heart, as generally indicated at block 544. As seen at block 546, the sense vector determined to produce the confidence level (e.g. signal-to-noise ratio (SNR)) may be used when sensing electrical cardiac signal associated with subsequent atrial contractions of the patient's heart.

FIG. 13 is a flow diagram showing another illustrative method for generating a ventricle pacing pulse. In some cases, the electrode arrangement used for sensing for an electrical cardiac signal associated with the atrial contraction may be configured to provide two or more sense vectors for sensing the electrical cardiac signal associated with the atrial contraction of the patient's heart. As generally seen at block 548, the method begins with sensing for the electrical cardiac signal associated with the atrial contraction of the patient's heart using each of two or more sense vectors of the two or more sense vectors of the electrode arrangement. As seen at block 550, the method includes determining a composite sense vector of the two or more sense vectors that increases the confidence level (e.g. signal-to-noise ratio (SNR)) relative to the confidence level (e.g. signal-to-noise ratio (SNR)) achievable by any one of the individual sense vectors. The composite sense vector may be used when sensing for electrical cardiac signals associated with subsequent atrial contractions of the patient's heart, as generally indicated at block 552.

Those skilled in the art will recognize that the present disclosure may be manifested in a variety of forms other than the specific examples described and contemplated herein. For instance, as described herein, various examples include one or more modules described as performing various functions. However, other examples may include additional modules that split the described functions up over more modules than that described herein. Additionally, other examples may consolidate the described functions into fewer modules. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present disclosure as described in the appended claims.

What is claimed is:

1. A method for generating a ventricle pacing pulse, comprising:
 - sensing for a mechanical response to an atrial contraction of a patient's heart;
 - sensing for an electrical cardiac signal associated with the atrial contraction of the patient's heart via an electrode arrangement;
 - weighting a timing associated with the sensed mechanical response to the atrial contraction with a first weight;
 - weighting a timing associated with the sensed electrical cardiac signal associated with the atrial contraction with a second weight different from the first weight;
 - determining an atrial contraction timing fiducial based at least in part on the weighted timing associated with the sensed mechanical response to the atrial contraction and the weighted timing associated with the sensed electrical cardiac signal associated with the atrial contraction; and
 - generating the ventricle pacing pulse after an A-V delay following the atrial contraction timing fiducial.
2. The method of claim 1, wherein the mechanical response to the atrial contraction of the patient's heart is sensed via an accelerometer of a Leadless Cardiac Pace-

maker (LCP) and/or an accelerometer of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

3. The method of claim 1, wherein the electrical cardiac signal associated with the atrial contraction of the patient's heart is sensed via an electrode arrangement of a Leadless Cardiac Pacemaker (LCP) and/or an electrode arrangement of a Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).

4. The method of claim 1, wherein the sensed mechanical response to the atrial contraction of the patient's heart is used to identify a time window in which an electrical cardiac signal is searched to identify the electrical cardiac signal associated with a subsequent atrial contraction.

5. The method of claim 4, wherein the sensed mechanical response includes the S3 and the S4 heart sounds, the time window is between the S3 to S4 heart sounds, and the electrical cardiac signal associated with the atrial contraction is a p-wave of an electrocardiogram signal.

6. The method of claim 1, wherein:

- the sensed mechanical response to the atrial contraction of the patient's heart has a signal-to-noise ratio (SNR);
- the sensed electrical cardiac signal associated with the atrial contraction has a signal-to-noise ratio (SNR);
- wherein when the signal-to-noise ratio (SNR) of the sensed mechanical response to the atrial contraction of the patient's heart is above a SNR threshold, the atrial contraction timing fiducial is based more on the mechanical response to the atrial contraction of the patient's heart by weighting the timing associated with the sensed mechanical response more heavily; and
- wherein when the signal-to-noise ratio (SNR) of the sensed mechanical response to the atrial contraction of the patient's heart is below the SNR threshold, the atrial contraction timing fiducial is based more on the electrical cardiac signal associated with the atrial contraction of the patient's heart by weighting the timing associated with the sensed electrical signal more heavily.

7. The method of claim 1, further comprising:

- detecting an ambulatory activity level of the patient;
- wherein the atrial contraction timing fiducial is based more on the mechanical response to the atrial contraction of the patient's heart by weighting the timing associated with the sensed mechanical response more heavily when the detected ambulatory activity level is below an activity threshold; and
- wherein the atrial contraction timing fiducial is based more on the electrical cardiac signal associated with the atrial contraction of the patient's heart by weighting the timing associated with the sensed electrical signal more heavily when the detected ambulatory activity level is above the activity threshold.

8. The method of claim 1, further comprising:

- detecting a posture of the patient;
- wherein the atrial contraction timing fiducial is based more on the mechanical response to the atrial contraction of the patient's heart by weighting the timing associated with the sensed mechanical response more heavily when the patient is in a first posture; and
- wherein the atrial contraction timing fiducial is based more on the electrical cardiac signal associated with the atrial contraction of the patient's heart by weighting the timing associated with the sensed electrical signal more heavily when the patient is in a second posture that is different from the first posture.

9. The method of claim 1, wherein the electrode arrangement is configured to provide two or more sense vectors for

21

sensing the electrical cardiac signal associated with the atrial contraction of the patient's heart, the method comprising:

sensing for the electrical cardiac signals associated with one or more atrial contractions of the patient's heart using a first sense vector of the two or more sense vectors of the electrode arrangement;

sensing for the electrical cardiac signals associated with one or more atrial contractions of the patient's heart using a second sense vector of the two or more sense vectors of the electrode arrangement;

determining which of the first sense vector and the second sense vector produces the higher signal-to-noise ratio (SNR) for the electrical cardiac signal associated with the one or more atrial contractions of the patient's heart; and

using the sense vector determined to produce the higher signal-to-noise ratio (SNR) when sensing electrical

22

cardiac signal associated with subsequent atrial contractions of the patient's heart.

10. The method of claim 1, wherein the electrode arrangement is configured to provide two or more sense vectors for sensing the electrical cardiac signal associated with the atrial contraction of the patient's heart, the method comprising:

sensing for the electrical cardiac signal associated with the atrial contraction of the patient's heart using each of two or more sense vectors of the two or more sense vectors of the electrode arrangement;

determining a composite sense vector of the two or more sense vectors that increases the signal-to-noise ratio (SNR) relative to a SNR achievable by any one of the individual sense vectors; and

using the composite sense vector when sensing for electrical cardiac signals associated with subsequent atrial contractions of the patient's heart.

* * * * *